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INTRODUCTION 
 
Over the last three decades there has been a decline in cardiovascular disease (CVD) 
mortality worldwide in all age groups and for both sexes.1 Despite this improvement, 
CVD is still the leading cause of death worldwide (Figure 1).1,2 There are important  
differences between men and women in the development of CVD and the impact  of 
the traditional risk factors.  For the risk of acute coronary syndromes, smoking in 
young women (<55 years) is relatively more important than in similarly aged men3,4, 
whereas smoking-associated risk for stroke is comparable between both genders.5 
Diabetes has a relatively higher CVD mortality risk in women than in men.6 In young 
men, hypertension is more prevalent than in women; however, the opposite is true in 
females after menopause.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Death by cause in Europe for men (top) and women (bottom), from Nichols 
et al.1 CHD, coronary heart disease; CVD, cardiovascular disease. 
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Beside these gender differences in classic CVD risk factors, several female-specific 
risk factors have been identified, mostly related to reproductive factors. Circulating 
estrogens are important for maintaining normal endothelial and vascular function in 
premenopausal women. Hormonal dysfunction or estrogen deficiency, which develops 
during menopausal transition, is associated with the development of vascular 
dysfunction and an adverse CVD risk profile.8-10 Early menopause is associated with an 
increased CVD risk and emerging data indicate that menopausal age and vasomotor 
symptoms in menopausal transition reflects vascular health status.11,12 On the other 
hand, a premenopausal harmful CVD risk factor profile is also associated with early 
menopause.13 
Earlier in women’s lives, pregnancy-related complications may be the first 
manifestation of an increased predisposition to CVD.14,15 Hypertensive pregnancy 
disorders (HPD) complicate about 10% of all pregnancies and cover a spectrum of 
conditions: gestational hypertension (GH), chronic hypertension and preeclampsia 
(PE). Women with a history of HPD, especially preeclampsia are at increased risk for 
earlier manifestation of various CVD risk factors post pregnancy, such as an elevated 
BMI, higher blood pressure and unfavourable lipid values.16 Besides the importance of 
preeclampsia as a cause of pregnancy-related disease and death17,18, it is therefore also 
important for health later in life. Several population-based studies have shown that 
decades later the prevalence of CVD is at least doubled in women post PE compared to 
women with uncomplicated pregnancies.14,19,20 More severe and recurrent HPD are 
associated with a higher risk of CVD (Figure 2).21,22 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2: Graded relation between severity PE and cardiac disease and death, from McDonald 2008.20  
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Despite our knowledge on adverse long-term prognosis, data on the course of the 
development of CVD risk factors from pregnancy onwards are relatively scarce. 
Knowledge on intermediate-term CVD risk factors are necessary to understand the 
disease process in these young women and to determine at what moment postpartum 
preventive actions should be undertaken. In the latest 2011 guidelines of the American 
Heart Association on CVD prevention in women, it has been emphasized that HPD are 
important female specific cardiovascular risk factors.23 It is recommended to monitor 
emerging CVD risk factors carefully in this subset of women, although concrete 
preventive measures are lacking. Currently, the follow-up of women with a history of 
PE is insufficient in primary care.24 To develop more detailed preventive guidelines in 
these potential high risk women, additional information on the pathophysiological 
mechanism of CVD development and evaluation of the effectiveness of postpartum 
(lifestyle) interventions is needed.25 
 
 
OBJECTIVES 
 
The main aim of this thesis is to investigate the development of CVD risk in women 
with a history of the various manifestations of HPD, i.e., preeclampsia and gestational 
hypertension, at intermediate term postpartum. We will focus on the presence of 
traditional CVD risk factors, but also on first diagnostic signs of existing CVD. 
Furthermore, we are interested in the timing and (cost)-effectiveness of routine follow-
up and treatment of CVD risk parameters in women post HPD. 
As described, female-specific CVD risk factors are involved in the development of 
CVD in women. Our second purpose is to evaluate the presence of various female-
specific risk parameters next to the traditional CVD risk factors in women. 
 
 
OUTLINE OF THIS THESIS 
 
In CHAPTER 2, we summarize the clinical spectrum of the various manifestations of 
HPD, and summarize the current knowledge on the etiology of PE and future risk to 
develop chronic hypertension. The longitudinal differences in traditional CVD risk 
factors between women with and without a history of gestational hypertension in a 
large population based cohort study (Doetinchem Cohort Study) are described in 
CHAPTER 3. Prevalence of CVD risk factors in a specific population of women post 
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early PE, based on the PREVFEM (Preeclampsia Risk EValuation in FEMales) cohort, 
are described in CHAPTER 4. In CHAPTER 5 we analyze ECG parameters at 10 years 
post index pregnancy and in unaffected controls from the PREVFEM-study. In 
CHAPTER 6 we evaluate a subset of novel cardiovascular and inflammatory biomarkers 
in the PREVFEM cohort. Subsequently, in CHAPTER 7 we describe the cost-
effectiveness of screening for hypertension in women with a history of early pre-
eclampsia. 
In CHAPTER 8 we make a side-step to the female-specific CVD risk factors and 
describe the association between a history of HPD and presence, frequency, severity 
and intensity of vasomotor symptoms. 
CHAPTERS 9 and 10 contain the general discussion and summary of the above-
mentioned chapters. 
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ABSTRACT  
 
Preeclampsia is a complication of pregnancy that has also long-term effects on 
maternal health. Several epidemiologic studies have shown an increased risk for 
cardiovascular morbidity (relative risk [RR] 2.3) and mortality (RR 2.3) in women 
after a history of preeclampsia. The chance to develop chronic hypertension afterwards 
is 2-fold to 10 times higher in affected women, compared with women after normo-
tensive pregnancies. As hypertension is a major cardiovascular risk factor, early 
detection and treatment is mandatory to reduce the risk of future cardiovascular 
disease. Data on (cost)-effectiveness of cardiovascular screenings programs in women 
after preeclampsia are currently lacking and there are no recommendations yet for 
prevention in the guidelines. We recommend regularly preventive blood-pressure 
measurements after high-risk pregnancies. More research is needed to identify women 
who will profit most of early intervention.  
 
 
INTRODUCTION 
 
Hypertensive disorders complicate 10% of all pregnancies and cover a spectrum of 
conditions including chronic (essential) hypertension, gestational hypertension, 
preeclampsia and the HELLP (Haemolysis, Elevated Liver enzymes and Low Platelets) 
syndrome. 
Of these conditions, preeclampsia is the most important in absolute numbers of 
maternal and fetal morbidity and mortality. Besides the perinatal complications, 
preeclampsia has also long-term consequences for maternal health. Several 
epidemiological surveys have shown an association between preeclampsia and an 
increased risk for the development of hypertension and cardiovascular disease (CVD) 
later in life.1-7 The underlying etiology of preeclampsia and future cardiovascular 
consequences is still debated, although both conditions share similar risk factors such 
as hypertension, elevated insulin resistance and dyslipidemia.8-10  
In this review we discuss the hypertensive disorders of pregnancy, especially 
preeclampsia, and the current knowledge for their consequences on future maternal 
blood pressure. 
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Table 1: Definitions of hypertensive pregnancy disorders 
Type of disorder Blood pressure Duration of gestation Other symptoms 
Chronic  
  hypertension 
≥140/90 mmHg Before pregnancy, òr in first  
   20 weeks of gestation 
– 
    
Gestational 
  hypertension 
≥140/90 mmHg >20 weeks of gestation until 
   12 weeks postpartum 
– 
    
Preeclampsia ≥140/90 mmHg >20 weeks of gestation until 
   12 weeks postpartum 
Proteinuria 
  ≥0.3 g/24 h 
    
HELLP 
syndrome 
Not defined >17 weeks of gestation until  
   1 week postpartum 
hemolysis 
liver failure 
trombopenia  
proteinuria 
 
 
CLINICAL SPECTRUM OF HYPERTENSIVE DISORDERS IN PREGNANCY  
(TABLE 1) 
 
Chronic hypertension 
Chronic hypertension complicates approximately 3% of all pregnancies and is defined 
as a blood pressure >140/90 mmHg that already exists before gestation or arises before 
the 20th week of pregnancy. Chronic hypertension is more prevalent in women with 
advanced age (>35 years) during pregnancy and in obese women.9,11 It has a benign 
course, with often normalisation of blood pressure during midpregnancy. 
Antihypertensive medication is indicated when systolic blood pressure is higher than 
150 mmHg or a diastolic pressure above 100 mmHg or when signs of hypertensive 
end-organ damage (nephropathy, left ventricular hypertrophy, retinopathy) are present. 
It is unknown whether adequate treatment of chronic hypertension in pregnancy may 
prevent the superposition of preeclampsia. Excessive lowering of blood pressure 
however may result in placental hypoperfusion and induce an adverse fetal outcome.9,12 
 
Gestational hypertension 
Gestational hypertension is defined as a systolic blood pressure >140 mmHg or a 
diastolic blood pressure >90 mmHg, occurring in the second half of pregnancy in 
previously normotensive women. Blood pressure has to be normalized at 12 weeks 
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postpartum. If hypertension does not resolve postpartum the condition is diagnosed as 
chronic hypertension.9,1 Gestational hypertension occurs in about 8-10% of 
pregnancies. In about one third of these women, gestational hypertension will progress 
into preeclampsia.11 The relative risk of future hypertension is between 1.7 and 7.2, 
depending on the years of follow-up and the severity of gestational hypertension.7,13,14 
Fetal consequences are mainly dependent on duration of pregnancy at delivery and 
birth weight.15 
 
Preeclampsia  
Preeclampsia, occurring in 3-5% of pregnancies, is defined as hypertension >140/90 
mmHg and proteinuria >0.3 g/24 h occurring after the 20th week of gestation. 
Remission of symptoms of preeclampsia (hypertension and proteinuria) is induced by 
delivery, although in a small portion of women symptoms do persist postpartum. Sub- 
classifications can be made into mild preeclampsia (hypertension >140-159/90-99 
mmHg and proteinuria >0.3-2.9 g/24 h) and severe preeclampsia (hypertension 
>160/100 mmHg or proteinuria  >3.0 g/24 h). Preeclampsia can also be divided in early 
and late onset, referring at the gestational age when symptoms reveal. In early 
preeclampsia symptoms appear before 28 weeks of gestation. Fetal consequences of 
preeclampsia are preterm birth and growth retardation with low birth weight, which are 
both important causes of neonatal death. Globally preterm birth (<37 weeks of 
gestation) accounts for a quarter of neonatal deaths, which is defined as death in first 
28 days after delivery. Low birth weight, is an important indirect cause of 60-80% of 
neonatal deaths.15,16 The risk of ischemic heart disease and mortality is at least 2-fold 
higher in women with a history of preeclampsia compared with women with 
normotensive pregnancies.1-3,6 Preeclampsia occurs most often in first pregnancies, 
however, the risk of recurrence is high estimated at 30-50%. In women with a history 
of early preeclampsia (symptoms before 28 weeks of gestation) the recurrence rate is 
even higher.16,17 
Eclampsia is the convulsive form of preeclampsia and affects approximately 0.1% of 
all pregnancies. Seizures are most plausibly caused by hypertensive encephalopathy.17 
The risk of recurrent eclampsia is low, while the recurrence rate of preeclampsia 
remains high.18 
 
HELLP syndrome 
The HELLP syndrome is a severe form of preeclampsia with the clinical syndrome of 
renal failure, liver failure, disseminated intravascular coagulation and central nervous 
dysfunction (cerebral edema, seizures, headaches). It occurs in 10-20% of women with 
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signs of preeclampsia and leads to urgent delivery with a high maternal and fetal 
mortality rate (7-20%).11,19 Blood pressure levels are not typically very high, but can be 
moderately elevated, sometimes even without proteinuria.9 Recurrence of the HELLP 
syndrome is low, approximately 2-5%. However, up to 50% of these women will 
develop hypertension in subsequent pregnancies.20 Data on future cardiovascular (CV) 
risk post HELLP syndrome is scarce, the chance to develop chronic hypertension after 
3-5 years of follow-up varies from 6-33%.21-23 
 
 
ETIOLOGY OF PREECLAMPSIA IN PREGNANCY  
 
There are many theories about the etiology of preeclampsia, it is therefore called the 
‘disease of theories’.24 Mechanisms involved in its pathophysiology are an abnormal 
placentation, constitutional factors of the mother (CV risk factors and familiar 
occurrence of pregnancy-related complications) and an exaggerated metabolic response 
on pregnancy. Inadequate trophoblast invasion of the spiral arteries in the placenta bed 
leads to hypoperfusion and ischemia of the placenta. This causes an activation and 
dysfunction of the maternal endothelium with vasoconstriction and an enhanced 
vascular permeability of the maternal blood vessels. This results in clinical signs of 
preeclampsia in the mother with the development of hypertension, proteinuria and 
oedema.8,9,25 Several metabolic components in the maternal circulation further 
contribute to the activation of the endothelium. Many serum levels of inflammatory 
markers such as cytokines, leucocytes and a variety of cellular adhesion molecules 
(TNFα,IL-2, IL-6, VCAM-1, ICAM-1, E-selectin) are up-regulated. During normal 
pregnancy coagulation factors (factor V, VII, VIII, von Willebrand, X, XII) and 
platelets are elevated while fibrinolysis is suppressed. In preeclampsia however this 
response is exaggerated, leading to a hypercoaguability state. The occurrence of micro-
vascular thrombi in different organs (e.g., kidney, cerebrum) is therefore very common. 
Triglycerides, low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) 
rise to very high levels during preeclampsia, while high-density lipoprotein (HDL) 
levels are very low. These changes in serum lipid levels may further contribute to the 
endothelial damage in the mother.8  
 
Oxidative stress 
The vascular lesions in the placenta bed, due to ischemia, are called ‘acute atherosis’ 
and are characterized by fibrosis, foam cells, fibroblast proliferation and a mononuclear 
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cell perivascular infiltrate. These lesions are comparable with early atherosclerotic 
plaque formations in CVD disease. Oxidative stress plays an important role in the 
aetiology of atherosclerosis and may also be involved in the maternal response to 
placental ischemia. The release of free oxygen radicals, like superoxide aniones or lipid 
hydroperoxides, damages the endothelium and contributes to the development of 
atherosclerotic plaques.8,26 It is hypothesized that oxidative stress and acute atherosis 
may be the main causative factors in the increased CV risk in women with a history of 
preeclampsia.24 
 
Other triggers for preeclampsia 
Besides the abnormal placental vascularisation other triggers may be involved in the 
activation of the endothelium in preeclampsia. Infections (urinary tract infections) and 
pre-existent auto-immune diseases or coagulation disorders (like disseminated lupus 
erythematosus or hyperhomocysteinemia) have been mentioned.9,17,25 These underlying 
conditions may change the maternal responsiveness to pregnancy and provoke the 
clinical signs of preeclampsia.25 
 
Genetics 
Genetic factors are involved in the development of preeclampsia, both by the maternal 
and fetal genotype. A positive family history of preeclampsia (mothers and sisters) 
triples the risk of occurrence.27 Maternal susceptibility for preeclampsia may also be 
influenced by paternal antigens. This is in line with observations that primipaternity 
and a changed paternity in multiparous women are also risk factors for 
preeclampsia.24,28 Currently, investigations aim at the candidate gene theory (single 
genes only expressed in pregnancy), linkage genes (involved in maternal-fetal 
interaction) and associations with specific immunological genes (like the HLA 
system).24 
 
RAS (renin-angiotensin system) 
During pregnancy the RAS is activated in the uteroplacental unit by hypoperfusion of 
the placenta and this may mediate in the pathophysiology of hypertensive pregnancy 
disorders. In normal pregnancy levels of renin, angiotensin and aldosteron are elevated 
with less sensitivity to angiotensin II. Paradoxically, in preeclampsia sensitivity to 
angiotensin II is increased, resulting in a higher peripheral resistance and blood 
pressure. This leads to vasoconstriction in the kidneys and a deterioration of renal 
function with proteinuria.29,30 
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PREECLAMPSIA AND ATHEROSCLEROSIS, ASSOCIATED BY THE INSULIN 
RESISTANCE SYNDROME? 
Traditional CV risk factors like hypertension, dyslipidemia, obesitas and diabetes are 
more often pre-existent in women who develop hypertensive disorders in pregnancy. 
Postpartum the prevalence of these CV risk factors further increases.13,27,31-36 
Clustering of various risk factors in the metabolic syndrome is associated with an even 
higher risk of future CVD.37 In the CHAMPS-study (Cardiovascular Health After 
Maternal Placental Syndromes - study) an almost 12-fold increased risk of premature 
CVD was found in women with the combination of preeclampsia and the metabolic 
syndrome.3 Elevated insulin resistance is a common factor in both preeclampsia and 
atherosclerosis.38-42 The time of onset of preeclampsia (early vs late) is also important 
for the development of the metabolic syndrome. At 1 year postpartum the metabolic 
syndrome is two times more present in women with early-onset preeclampsia than in 
women with late-onset preeclampsia.43 Probably the metabolic syndrome is important 
in the development of both preeclampsia and cardiovascular disease on future age, 
however the exact mechanisms are not clear. 
 
 
DEVELOPMENT OF CHRONIC HYPERTENSION AFTER PREECLAMPSIA  
 
Several case-control and cohort studies have shown a higher risk of chronic 
hypertension after preeclampsia (Table 2).2,7,13,14,18,31,32,44-49 Mild and severe 
preeclampsia may have a different impact on the risk of chronic hypertension. Lykke et 
al.14 have made a subclassification into mild preeclampsia (hypertension and 
proteinuria) and severe preeclampsia, including signs of the HELLP syndrome. The 
relative risk (RR) of hypertension was 6.07 for severe preeclampsia compared with 
3.61 for mild preeclampsia.  
Gestational hypertension is generally considered a more benign condition in terms of 
perinatal morbidity and mortality in comparison with preeclampsia and the HELLP 
syndrome. Some studies however have reported a higher risk on chronic hypertension 
after gestational hypertension than with preeclampsia.13,47,48 Differences in definition 
of exposure in these studies may have caused this inconsistency. Others speculate on 
the heterogeneous expression of hypertensive diseases in pregnancy with a different 
pathophysiology.10,50 While early preeclampsia may be caused by placental 
dysfunction, late-onset preeclampsia may be the expression of a hypertensive condition 
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without placenta dysfunction. However, this does not explain the differences in 
prevalence of chronic hypertension later in life. 
 
 
RECOMMENDATIONS FOR PREVENTION OF CHRONIC HYPERTENSION AFTER 
PRE-ECLAMPSIA 
 
Hypertension is a major risk factor for the development of CVD in women. The 
worldwide prevalence of hypertension in all age-groups is estimated at about 26% and 
will rise up to 30% in the coming years.45 In the USA 75% of postmenopausal women 
develop hypertension that has to be medically treated.51,52 Antihypertensive treatment 
translates in significant reductions of cardiovascular morbidity and mortality, 
comparative in men and women.53 In the latest USA guidelines for CVD prevention in 
women there are no recommendations yet for women with a past history of 
preeclampsia.54 These are not formulated either in the latest European guidelines for 
the management of arterial hypertension.53 In current clinical practice monitoring of 
blood pressure post-partum is performed until clinical signs recover, usually several 
weeks post-partum. As the risk for chronic hypertension can be 1.50 to 12 times higher 
(see Table 2) in these women compared with normotensive women in pregnancy, 
regular controls of blood pressure are advisable. Lifestyle modifications are the first 
step in treatment of elevated blood pressure.53-55 Additional medical treatment of 
hypertension should be according to the current guidelines. So far there are no 
published follow-up data on the (cost)-effectiveness of cardiovascular screening/ 
monitoring programs in women after preeclampsia. Until further evidence confirms 
benefit of cardiovascular screening in women with a history of preeclampsia, there 
seems to be no place for preventive interventions other than lifestyle modification.  
 
 
PREVENTION OF PREECLAMPSIA 
 
Reducing the occurrence of preeclampsia will improve long-term maternal health. A 
healthy lifestyle is of primary importance, especially in women with a positive family 
history and the presence of several CV risk factors such as obesity. Other known risk 
factors for the development of preeclampsia are pre-existing auto-immune disease 
(antiphospholipid antibodies) and increased maternal age. Weight loss and adequate 
treatment of pre-existing cardiovascular risk factors can be effectuated in 
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preconception care. In pregnancy the women with identified high-risk for development 
of preeclampsia should be monitored more carefully in antenatal care for the 
development of symptoms (e.g., hypertension and proteinuria).27,55 Unfortunately, there 
is not one single diagnostic test (hormone markers or markers of placental 
insufficiency) which predicts the development of preeclampsia adequately. In the 
absence of a golden standard the search for a predictive test is even more difficult. 
Uterine artery Doppler assessment can be used to demonstrate inadequate trophoblast 
invasion in women at risk, but is of limited ability in screening, although a positive 
result increases the likelihood ratio by six. Genetic research may probably reveal some 
distinct features in the future to predict preeclampsia at an earlier stage.56,57 
In pregnant women with a history of preeclampsia prevention with aspirin can be 
considered, starting after the first 12 weeks of gestation, but the benefits are minor. 
Antihypertensive medication in pregnancy can be given conform the current obstetric 
guidelines.55-57 Calcium supplementation is only useful in women on low calcium 
intake.58 There is no evidence that other nutritional interventions or supplements 
(antioxidants, fish oil, sodium restriction) are effective to prevent (re-)occurrence of 
preeclampsia.55,56 
 
 
CONCLUSION 
 
Preeclampsia complicates about 3-5% of pregnancies, with serious consequences on 
maternal lifetime cardiovascular health. The risk to develop chronic hypertension later 
in life is high and guidelines for blood-pressure management post preeclampsia are 
currently lacking. Future research should focus on cost-effectiveness of CV screening 
programs in women afterwards. Physicians should be triggered by a history of 
hypertensive pregnancy disorders and provide surveillance for blood pressure with 
adequate lifestyle measurements in these potential high-risk women. 
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ABSTRACT 
 
Objective: Women with hypertensive pregnancy disorders (HPD) are at increased risk 
of developing hypertension and cardiovascular disease later in life; however, it is 
unknown how cardiovascular risk develops throughout life. We evaluated the 
longitudinal trends in cardiovascular risk factors in women after hypertensive 
pregnancy disorders compared to women with normotensive pregnancies. 
Design and population: All women of the Doetinchem Cohort Study (1987-1991), a 
population-based cohort study, were included. 
Methods: Women were examined (questionnaires and physical examination) four times 
at 5-year intervals. History of HPD was assessed from questionnaires. We compared 5-
year changes in risk factors between women with and without HPD, by analysing 
longitudinal trends using generalized estimating equation analysis to estimate the 
effects of HPD and mean age, adjusting for treatment, body mass index (BMI), 
smoking and social economic status. 
Main outcome measures: Change over time in traditional cardiovascular risk factors, 
including systolic blood pressure (SBP) and diastolic blood pressure (DBP), BMI, total 
and high-density lipoprotein (HDL) cholesterol for women with and without history of 
HPD. 
Results: A total of 2703 women with normotensive pregnancies (mean age 40.5 years, 
SD10.4) and 689 women with a history of HPD (mean age 38.4 years and SD 9.5) were 
included. Compared to normotensive women, in women with a history of HPD, SBP 
was 2.8 mmHg higher (95%CI 1.7; 3.9), DBP 2.3 mmHg higher (95%CI 1.6; 3.0) and 
BMI 0.7 kg/m2 higher (95%CI 0.4; 1.1). Total cholesterol (-0.05; 95%CI -0.1; 0.0) and 
HDL cholesterol (0.02; 95%CI -0.0; 0.1) were similar in both groups. No difference in 
annual change in blood pressure or in the other risk factors was observed between 
women with and without a history of HPD.  
Conclusion: Women with a history of HPD have higher levels of SBP, DBP and BMI 
compared to normotensive women, but the increase with ageing is similar in both 
groups. 
 
 
INTRODUCTION 
 
In the last decade differences in cardiovascular disease (CVD) between men and 
women have been extensively studied. Well-known cardiovascular risk factors such as 
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hypertension, hypercholesterolemia and diabetes mellitus are important for both 
genders. In addition, several female-specific risk factors have been identified, mostly 
connected with reproductive history.1-3 A history of complications in pregnancy, such 
as gestational diabetes, hypertensive pregnancy disorders (gestational hypertension, 
preeclampsia and HELLP [hemolysis, elevated liver enzymes and low platelet count] 
syndrome) and placental dysfunction have been associated with increased 
cardiovascular risk. The severity of pregnancy disorders is related to future 
cardiovascular risk.4-8 Women with a history of preeclampsia, defined as hypertension 
and proteinuria in the second half of pregnancy, have at least a two times higher risk of 
cardiovascular disease at older age.9-11 Gestational hypertension is more benign in 
terms of pregnancy outcome and long-term maternal health; however, risk of chronic 
hypertension and coronary artery calcification is also increased in these women.12-14 
Several hypotheses about the mechanism between hypertensive pregnancy disorders 
(HPD) and CVD have been postulated, and endothelial dysfunction seems to play a 
crucial role in the development of future CVD.15-19  
Until now there has been a gap in information on the development of cardiovascular 
risk between the ages of 40 and 60 years in women after HPD. A recent study showed 
an increased 10-year cardiovascular risk in women with a history of HPD 18 years 
postpartum compared to women with normotensive pregnancies or previous gestational 
diabetes.8 However, longitudinal follow-up data are not available. Current guidelines 
identify women with a history of gestational diabetes, GH and PE at risk for future 
cardiovascular disease, although there are no specific recommendations on timing of 
monitoring or prevention in these high-risk women;20 neither is there evidence on cost-
effectiveness of preventive measures in this target group.21-22    
The objective of this study is to gain more insight into the presence and development of 
cardiovascular risk factors over time in women with a history of HPD. In this study we 
investigate in a population-based cohort, the Doetinchem Cohort Study, the 
longitudinal trends in the cardiovascular risk factors blood pressure, body mass index 
(BMI), total cholesterol and high density lipoprotein (HDL) cholesterol in a subgroup 
of women with and without a history of HPD.  
 
 
METHODS 
 
Study population 
The Doetinchem Cohort Study is a prospective population-based study, set up to study 
the impact of (changes in) lifestyle factors and biological risk factors on health. 
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Between 1987 and 2007, four measurement rounds were completed. At baseline (R1: 
1987-1991), 12 405 inhabitants aged 20-59 years of Doetinchem, a town in a rural area 
of The Netherlands, were examined as part of the Monitoring Project on 
Cardiovascular Disease Risk Factors (MP-CDRF). From the first round, a random 
sample of 7769 participants was re-invited for a second examination (R2: 1993-1997), 
and again 5 and 10 years later for a third (R3: 1998-2002) and fourth (R4: 2003-2007) 
examination. A detailed description of the sampling and data collection procedures has 
been published previously.23 The study protocol was approved by the external Medical 
Ethics Committee of The Netherlands Organization of Applied Scientific Research 
Institute (TNO), and all participants provided written informed consent. To evaluate 
the effects of HPD we only selected the women in Doetinchem Cohort study (n=3392); 
throughout the study there were 2703 women without a history of HPD and 689 
women with a history of HPD (i.e., a positive answer on the question ‘Did you ever 
have high blood pressure in pregnancy.’).   
 
Outcome variables 
Biological risk factors: The biological risk factors of interest for the present study that 
were collected in each round included (1) systolic blood pressure (SBP) and diastolic 
blood pressure (DBP), (2) total and HDL cholesterol and (3) height and weight. Body 
weight and height were measured in light indoor clothing with emptied pockets and 
without shoes. Height was measured with a wall-mounted stadiometer to the nearest 
0.5 cm. Body weight was measured with a balance beam scale to the nearest 0.5 kg. 
BMI was calculated as weight (kg) divided by height (m) squared. Blood pressure was 
measured twice, with the participant in sitting position. The mean value of the two 
measurements was used in the analysis. In R1-3 blood pressure (BP) was measured 
with a random zero sphygmomanometer (Hawksley & Sons, Lancing, UK) and the first 
and the fifth phase Korotkoff sounds are the criteria for SBP and DBP, respectively. In 
examination R4, BP was measured by means of an automated Speidel-Keller meter 
(Welch Allyn, Skaneatelles Falls NY, USA). In all rounds, a 30-ml non-fasting serum 
blood sample was drawn. Total and HDL cholesterol were determined at the Lipid 
Reference Laboratory of the Erasmus Medical Center in Rotterdam, using an 
automated enzymatic procedure.  
 
Cardiovascular risk factors: Hypertension was defined as a SBP >140 mmHg and/or a 
DBP of >90 mmHg and/or use of antihypertensive medication. Presence of diabetes 
mellitus (DM) was defined as self-reported treatment for DM; hypercholesterolemia as 
 
Cardiovascular risk post hypertensive pregnancy disorders 
___________________________________________________________________ 
28 
 
non-fasting total cholesterol ≥6.5 mmol/l and/or use of statins. Smoking was defined as 
current smoking, ex-smoking or no smoking.  
 
Other variables: In each round, participants completed a questionnaire on demographic 
characteristics, lifestyle characteristics and presence of chronic diseases or risk factors 
thereof. Use of antihypertensive medication and cholesterol lowering therapy was 
classified into yes/no. Educational level was assessed as the highest level of completed 
education during follow-up and classified into three categories: low (intermediate 
secondary education or less), medium (intermediate vocational or higher secondary 
education) and high (higher vocational education or university). A history of HPD was 
defined by self-reported history of hypertensive pregnancy disease. This was based on 
a positive answer of the question ‘Did you ever have high blood pressure in pregnancy’ 
at one of the four rounds. A history of gestational diabetes was also based on self-
reported history. 
 
Data analysis 
Baseline characteristics were described as mean with standard deviation for continuous 
data, and as percentages for categorical data. Differences between women with and 
without HPD for continuous data were analyzed by Student’s t-test for independent 
groups and for categorical data with Chi-square or Fisher exact test when appropriate.  
To evaluate the effect of HPD and age on blood pressure, cholesterol measurements 
and BMI over the follow-up time we used generalized estimating equation analyses 
(GEE) with the GENMOD procedure in SAS software (SAS Institute, Cary, NC, 
USA). The GEE procedure extends the generalized linear model to allow for analysis 
of repeated measurements at different time points. The intercept of this model is an 
estimate of the difference in risk factor between women with and without HPD. For 
this analysis we modeled HPD time-dependently, which means that women were 
defined as having had HPD from the moment on they reported first HPD. The 
regression coefficient is an estimate of the annual change in risk factor. Whether 
presence of HPD yes or no modifies the age-related increase in risk factors was 
evaluated by including the interaction term ‘HPD x age’ into the model. Adjustments 
for use of antihypertensive medication, statins, BMI, smoking and social-economic 
status (SES) were made. All p values were two-sided, statistical significance was 
assumed when two tailed probability value was <0.05. 
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RESULTS 
 
Table 1 shows characteristics of the Doetinchem women at all four follow-up rounds. 
Table 2 shows the regression analysis of the different continuous cardiovascular risk 
factors (SBP and DBP), BMI and cholesterol (total and HDL) for presence of HPD, 
ageing and interaction between HPD and age.  
Blood-pressure levels were significantly higher in the women with a history of HPD 
compared to those without HPD. SBP was 3.10 mmHg (95%CI 1.95; 4.25) higher and 
DBP 2.58 mmHg (95%CI 1.87; 3.29) higher in women with HPD compared to women 
without history of HPD. Adjustment for use of antihypertensive medication, statins, 
BMI, smoking and SES in the model slightly decreased the blood-pressure differences 
between both groups, but differences remained statistically significant, SBP 2.78 
mmHg (95%CI 1.69; 3.87) higher and DBP 2.30 mmHg (95%CI 1.62; 2.98). No 
interaction effect for the presence of HPD and age-related increase in blood pressure 
was observed: the increase in blood pressure was 0.84 mmHg (95%CI 0.80; 0.88) per 
year for SBP and 0.29 mmHg (95%CI 0.26; 0.31) per year for DBP in both groups.  
Body mass index was also significantly different between both groups, 0.64 kg/ m2 
higher (95%CI 0.29; 0.99) in women with a history of HPD; the yearly BMI increase 
was not different according to HPD (0.10 m2/kg (95%CI 0.09; 0.11) per year. 
Adjustment for potential confounders did not change the BMI differences between the 
groups nor the annual BMI increases in women. 
At rounds 1 and 2, total cholesterol was higher in women without history of HPD, later 
this difference disappeared. HDL levels were similar at each round. After full 
adjustment, total and HDL cholesterol levels did not differ between women with and 
without history of HPD (difference between groups -0.05 mmol/l; 95%CI -0.13; 0.03 
for total cholesterol, and 0.02 mmol/l; 95%CI -0.01; 0.05, for HDL cholesterol). A 
history of HPD also did not influence yearly changes of total and HDL cholesterol.  
Prevalences of other traditional cardiovascular risk factors are described in Table 1. 
Smoking prevalence was lower in women with HPD at rounds 1 to 3. Prevalence of 
hypertension was not different between both groups, although use of antihypertensive 
medication was more prevalent in women without history of HPD at rounds 1 to 3. 
Prevalence of hypercholesterolemia, DM and family history of myocardial infarction 
was similar in both groups of women. Women with a history of HPD had more often 
previous gestational diabetes compared to women without hypertensive pregnancy 
complications (6% for women with HPD and 3% in women without HPD at round 4).  
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DISCUSSION 
 
Main findings 
In this longitudinal population-based cohort study we observed that in women with a 
history of HPD mean SBP is 3 mmHg higher, mean DBP 2 mmHg higher and mean 
BMI 0.7 kg/m2 higher, compared with women without history of HPD. Increases in 
blood pressure and BMI with age did not differ between the two groups. Mean levels 
of total and HDL-cholesterol did not differ between women with and without a history 
of HPD.  
 
Strengths and weaknesses 
Our study has several limitations that have to be taken into account. An important 
limitation is the assessment of the self-reported history of hypertensive pregnancy 
disorders, based on the questionnaire. This precluded us from differentiating between 
mild and severe conditions. Furthermore, mild conditions may have been under-
reported, resulting in misclassification. This misclassification of mild cases of HPD as 
normotensive women will however only have led to an underestimation of the true 
magnitude of the associations, and could be a good explanation for the modest changes 
in blood pressure and BMI we found in our study compared with other studies in 
literature.8,19 Besides this, we lack information on the timing of the affected pregnancy 
and the severity of the reported HPD, that may vary from limited GH to full-blown 
severe preeclampsia or HELLP syndrome. Previous studies have shown that this has 
important consequences for future cardiovascular risk.7 In the women with a history of 
HPD in our analysis the complete spectrum of hypertensive pregnancy disorders will 
be present. Data in women with severe preeclampsia only will result in larger effects, 
as we previously demonstrated.24  
Important strengths of our study are that we had data from almost 3400 young women 
from the general population with an extensive follow-up and high response rates during 
follow-up, between 75 and 80%. Additionally, risk factors were measured four times 
over a period of 20 years, with direct contact with the participants at each round. We 
were able, for the first time, to study the role of HPD in CVD risk factor patterns over 
time. As intermediate cardiovascular follow-up data in affected women are scarce, our 
study adds valuable information to the field of cardiovascular risk in women with 
history of hypertensive diseases of pregnancy. 
 
 
 
Cardiovascular risk post hypertensive pregnancy disorders 
___________________________________________________________________ 
32 
 
Interpretation 
Several studies identified the increased risk of CVD for women with a history of 
hypertensive pregnancy diseases, especially preeclampsia.4-8 Prevalence of chronic 
hypertension, an important risk factor for CVD, is also high in this subset of women.13 
As we have underlined before, little is known about the course of development of 
cardiovascular risk factors after having experienced gestational hypertension. A recent 
study identified an increased 10-year cardiovascular risk (based on Framingham risk 
score) in women with a history of pregnancy disorders (18 years post partum).8 To our 
knowledge our study is the first analysis of longitudinal data on cardiovascular risk 
factors in women with previous HPD. We observed that blood pressures and BMI 
levels in these women are significantly higher at all time periods during follow-up, 
which is consistent with the literature.17-19 However, the impact on clinical significance 
of the observed differences is limited and further research should confirm our data. The 
established differences between both groups do not further increase during follow-up. 
This information might shed some light on the different hypotheses about the relation 
between hypertensive pregnancy disorders and future cardiovascular disease. From 
round 1 onwards, the exposed women are different, giving support to the hypothesis 
that the endovascular system of affected women has changed before pregnancy. In this 
study we were not able to evaluate the effect of prepregnancy factors, because we do 
not know the exact timing of the HPD in these women.   
For other traditional cardiovascular risk factors, like lipids, we did not find a difference 
between women with a history of HPD compared to women with normotensive 
pregnancies. This is unexpected, as other studies have found a more unfavorable lipid 
profile in women with a history of HPD compare to reference women.17,25 The possibly 
more limited severity of the previous HPD in our cohort could be the reason for these 
findings. Women with a history of HPD were less often smokers, while previous 
smoking was similar within both groups. These factors therefore do not explain the 
known increased cardiovascular risk for women with a history of HPD. Blood pressure 
and BMI seem to be the most important factors for future cardiovascular risk in this 
subset of women. Unfortunately, our study was not powered to evaluate differences in 
cardiovascular events over time for women with and without history of HPD.   
The latest American Heart Association guidelines for CVD prevention in women 
mention pregnancy disorders as risk factor for future CVD and advise taking a detailed 
obstetric history in women and monitoring their risk factors carefully.20 This is not yet 
common daily practice however, so more efforts are needed to create awareness among 
clinicians and their patients. According to our present data, measurements of blood 
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pressure and lifestyle advice are to be recommended for women with a history of HPD 
between 40 to 55 years of age. The clinical impact in the long-term is unclear. 
To further elucidate the relation between hypertensive pregnancy disorders and CVD 
risk we suggest that future research should focus on lifetime development of risk 
factors with additional pre-pregnancy measurements, careful registration of pregnancy 
disorders and long-term follow-up postpartum. In parallel, the effects of possible 
preventive measures should be evaluated. 
 
 
CONCLUSION 
 
In this longitudinal population-based cohort study we observed that women with a 
history of HPD have significantly higher blood pressure and BMI compared with 
women without a history of HPD. During follow-up both blood pressure and BMI 
increase similarly with age in both groups. Based on these data we could not advise 
long-term monitoring of cardiovascular risk factors post partum for women with a 
history of HPD. Future research should focus on careful registration of pregnancy 
disorders, preferably with information on pre-pregnancy risk factor levels and 
evaluation of lifetime development of cardiovascular risk factors. 
 
  
 
Cardiovascular risk post hypertensive pregnancy disorders 
___________________________________________________________________ 
34 
 
REFERENCES 
 
1. Shaw LJ, Bugiardini R, Merz CN. Women and ischemic heart disease: evolving knowledge. J 
Am Coll Cardiol 2009;54:1561-1575. 
2. Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early 
menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 
2006;13:265-279. 
3. Bilhartz TD, Bilhartz PA, Bilhartz TN, Bilhartz RD. Making use of a natural stress test: 
pregnancy and cardiovascular risk. J Women’s Health 2001;20:695-701.  
4. Rich-Edwards JW, McElrath TF, Karumanchi SA, Seely EW. Breathing life into the lifecourse 
approach: pregnancy history and cardiovascular disease in women. Hypertension 2010;56:331-
334.  
5. Smith GSC, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart 
disease: a retrospective cohort study of 129 290 births. Lancet 2001;357:2002-2006. 
6. Wikström AK, Haglund B, Olovsson M, Lindeberg SN. The risk of maternal ischaemic heart 
disease after gestational hypertensive disease. BJOG 2005;112:1486-1491. 
7. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal 
placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 
2005;366:1797-1803. 
8. Fraser A, Nelson SA, Macdonald-Wallis C, Cherry L, Butler E, Sattar N, et al. Associations of 
pregnancy complications with calculated CVD risk and cardiovascular risk factors in middle 
age: the Avon longitudinal study of parents and children. Circulation 2012;125:1367-1380. 
9. Steegers EAP, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010;376: 
631-644. 
10. McDonald SD, Malinowski A, Zhou Q, Yusuf S, Devereaux PJ. Cardiovascular sequelae of 
preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J 2008;156:918-930. 
11. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular 
disease and cancer in later life: systematic review and meta-analysis. BMJ 2007;335:974-977. 
12. Marín R, Gorostidi M, Portal CG, Sánchez M, Sánchez E, Alvarez J. Long-term prognosis of 
hypertension in pregnancy. Hypertens Pregnancy 2000;19:199-209.  
13. Drost JT, Maas AHEM, van Eyck J, van der Schouw YT. Preeclampsia as a female-specific risk 
factor for chronic hypertension. Maturitas 2010;67:321-326.  
14. Sabour S, Franx A, Rutten A, Grobbee DE, Prokop M, Bartelink ML, et al. High blood pressure 
in pregnancy and coronary calcification. Hypertension 2007;49:813-817. 
15. James JL, Whitley GS, Cartwright JE. Pre-eclampsia: fitting together the placental, immune and 
cardiovascular pieces. J Pathol 2010:221;363-378. 
16. Williams D. Pregnancy: a stress test for life. Curr Opin Obstet Gynaecol 2003;15:465-471.  
17. Romundstad PR, Magnussen EB, Smith GD, Vatten LJ. Hypertension in pregnancy and later 
cardiovascular risk common antecedents? Circulation 2010;122:579-584. 
18. Smith GN, Walker MC, Liu A, Wen SW, Swansburg M, Ramshaw H, et al; Pre-Eclampsia New 
Emerging Team (PE-NET). A history of preeclampsia identifies women who have underlying 
cardiovascular risk factors. Am J Obstet Gynecol 2009;200:58.e1-58.e8.  
 
Chapter 3 
___________________________________________________________________ 
35 
 
19. Sattar N, Ramsay J, Crawford L, Cheyne H, Greer IA. Classic and novel risk factor parameters 
in women with a history of preeclampsia. Hypertension 2003;42:39-42. 
20. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-
based guidelines for the prevention of cardiovascular disease in women – 2011 update a 
guideline from the American Heart Association. Circulation 2011;123:1243-1262. 
21. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, de Backer G, et al, on behalf of the 
SCORE project group. Estimation of ten-years risk of fatal cardiovascular disease in Europe: the 
SCORE project. Eur Heart J 2003;24:987-1003. 
22. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. 
European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task 
Force of European and other Societies on cardiovascular disease prevention in clinical practice. 
Eur Heart J 2003;24:1601-1610. 
23. Verschuren WMM, Blokstra A, Picavet HSJ, Smit HA. Cohort profile: The Doetinchem Cohort 
Study. Int J Epidemiol 2008;37:1236-1241. 
24. Drost JT, Arpaci G, Ottervanger JP, de Boer MJ, van Eyck J, van der Schouw YT, Maas 
 AHEM. Cardiovascular risk factors in women 10 years post early preeclampsia: the 
Preeclampsia Risk Evaluation in FEMales study (PREVFEM). Eur J Prev Cardiol 2012; 
19:1138-1144. 
25. Magnussen EB, Vatten LJ, Smith GD, Romundstad PR. Hypertensive disorders in pregnancy 
and subsequently measured cardiovascular risk factors. Obstet Gynaecol 2009; 114: 961-970. 
 
 
 

 
 
 
CHAPTER 4 
 
 
 
Cardiovascular risk factors in women 10 years 
post early preeclampsia: the Preeclampsia Risk 
EValuation in FEMales study (PREVFEM) 
 
 
 
 
 
José T. Drost,  
Ganiye Arpaci  
Jan Paul Ottervanger  
Menko Jan de Boer  
Jim van Eyck  
Yvonne T. van der Schouw  
Angela H.E.M. Maas 
 
 
 
 
 
 
 
 
 
 
 
 
Eur J Prev Cardiol 2011;19:1138-1144 
 

 
Chapter 4 
___________________________________________________________________ 
39 
 
ABSTRACT 
 
Introduction: Preeclampsia is a complication of pregnancy and a known risk factor for 
cardiovascular disease (CVD) later in a women’s life. The best approach for prevention 
of CVD in affected young women is yet unclear. We sought to investigate the 
prevalence of cardiovascular risk factors in women at 10 years post preeclampsia in 
comparison with a reference group.  
Methods: Women with a history of early preeclampsia (exposed), DBP >90 mmHg 
with proteinuria >0.3 g/24 h before 32 weeks of gestation, and an equal number of 
women after uncomplicated pregnancy (non-exposed) from the obstetric database of 
1991-2007, were sent a questionnaire and invited for a cardiovascular screening 
program.  
Results: 339 exposed women and 332 non-exposed women, 10 years post index-
pregnancy, were included in the current study. Systolic and diastolic blood pressures 
(SBP/DBP) were 127/86 versus 119/79 mmHg in the exposed and reference group 
respectively (p<0.001). Exposure to early preeclampsia was associated with a 3-fold 
increased prevalence of hypertension (adjusted odds ratio (OR) 3.59, 95%CI 2.48; 
5.20). BMI and waist circumference were 26.9 kg/m2 and 86.5 cm in exposed group 
and 26.2 kg/m2 (p=0.07) and 83 cm (p=0.001)in non-exposed group. We found no 
differences in levels of glucose, lipids and CRP. Adjusted OR for the metabolic 
syndrome in women post preeclampsia was 2.18 (95%CI 1.34; 3.52) compared with 
women in the reference group. 
Conclusion: We found a high prevalence of hypertension in young women at 10 years 
post early preeclampsia. More research on the timing of cardiovascular screening in 
these high-risk women is needed. 
 
 
INTRODUCTION 
 
Preeclampsia occurs worldwide in 3-5% of all pregnancies, in The Netherlands the 
prevalence is about 1%.1 Preeclampsia is defined as de novo blood-pressure elevation 
>140/90 mmHg with proteinuria >0.3 g/ 24 h occurring after the 20th week of 
gestation. Symptoms of early preeclampsia arise between 20-32 weeks of pregnancy.2,3 
An increasing number of reports over the past decade have shown that preeclampsia 
may serve as a risk factor of future cardiovascular disease (CVD) in women.4-10 The 
risk of premature CVD is strongly related to the severity of the metabolic disturbances 
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that have occurred during pregnancy.5 The difficulty in studying future maternal health 
risks is related to the heterogeneity of the patients within most study cohorts.4-10  
Although the aetiology of preeclampsia is still debated and incompletely understood, it 
has been acknowledged that preeclampsia that occurs early in pregnancy (between 20-
32 weeks) has a different pathophysiology to late preeclampsia (symptoms after 32 
weeks of gestation).11,12 A key factor in the onset of early preeclampsia is an abnormal 
inflammatory response in the maternal circulation, provoked by placental arterial 
insufficiency as a consequence of failure of trophoblast invasion in the spiral arteries. 
This leads to vasoconstriction and activation of the thrombotic system in the mother.3 
The specific lesions in the vascular bed of the placenta that occur in preeclampsia show 
similarities with the initial process of atherosclerosis.13  
After delivery symptoms usually recover within 1 week and most women are dismissed 
from further obstetric follow-up after a control visit to the outpatient clinic (about 6 
weeks postpartum).11 A few decades later, however, CVD event rate is at least doubled 
in women after preeclampsia compared to women with uncomplicated pregnancies.4-10 
Since intermediate prospective follow-up data after preeclampsia are relative scarce, it 
is not known at which time interval cardiovascular (CV) risk factors appear and need to 
be targeted for prevention. The 2011 American Heart Association (AHA) guidelines on 
cardiovascular prevention in women recommend careful monitoring of risk factors 
following preeclampsia, without mentioning when monitoring and preventive 
measurements should be started.14 Furthermore, in subsets of women with early 
preeclampsia there may be identifiable patients who would benefit from early risk 
factor intervention more than others. In our present study we aimed to evaluate the 
occurrence of CV risk factors in young women at 10 years post early preeclampsia in 
comparison with an age-matched reference group. 
 
 
METHODS 
 
Population 
At the department of obstetrics at the Isala klinieken in Zwolle, The Netherlands, all 
pregnant women have been registered in a database since 1991. Early preeclampsia 
was defined (according to the International Society for the Study of Hypertension in 
Pregnancy (ISSHP) definition) as having had an elevated diastolic blood pressure >90 
mmHg with proteinuria (>0.3 g/24 h) between 20 and 32 weeks of gestation during 
index pregnancy, almost always followed by premature delivery (Caesarean section). 
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We invited all women registered in the early preeclampsia database as well as an equal 
number of age-matched females without preeclampsia from the regular obstetric 
database in the same time-period (1991-2007) to participate in the Preeclampsia Risk 
EValuation in FEMales (PREVFEM) study. Participants were included in the study 
after signing an informed consent form and were invited for a CV screening program at 
the department of Cardiology. Pregnant or lactating women were excluded from 
participation (n=10). Approval for the study was obtained from the institutional review 
board of the Isala klinieken in Zwolle. 
 
Measurements 
After inclusion, participants were asked to fill in a questionnaire on obstetric history, 
family history, other medical history (especially CVD and known presence/awareness 
of CV risk factors), life style behavior, current medication use and current health 
complaints. Cardiovascular familiar risk was in the questionnaire defined as CVD or 
treatment of cardiovascular risk factors (hypertension, DM and hypercholesterolemia) 
in a first degree family member before the age of 60 years.  
At a scheduled visit in the outpatient clinic of the Department of Cardiology a physical 
examination was performed by trained vascular nurses, consisting of measurements of 
length, weight, waist and hip circumferences, pulse rate and blood pressure. Blood 
pressure (Omron M7 machine) was measured after a period of 10 minutes rest at both 
arms, three times, in a sitting position and with the appropriate cuff size. We report the 
mean value of these blood-pressure measurements. A resting ECG (Welch Allyn 
appliance) was taken and fasting blood and urine samples were collected for local 
laboratory testing. We measured cholesterol profiles (Roche Modular P800), glucose 
(Roche Modular P800), Hb1Ac (Primus Ultra 2), CRP (Roche Modular P800) and 
fibrinogen (Sysmex CA-1500). In urine we screened for (micro-)albuminuria. All data 
were collected in an electronic case report form, provided by Diagram BV.  
 
Definition of cardiovascular risk factors 
Cardiovascular risk factors were defined as follows: hypertension as a systolic blood 
pressure (SBP) >140 mmHg, a diastolic blood pressure (DBP) >90 mmHg or use of 
antihypertensive medication. Adequate control of blood pressure was defined as SBP 
<140 mmHg and DBP <90 mmHg for women on antihypertensive medication. The 
presence of DM was defined as diagnosed DM with treatment (diet or medication) or 
fasting glucose >7.0 mmol/l and hypercholesterolemia as total cholesterol >5.0 mmol/l 
or current use of statins. The metabolic syndrome (MetS) is defined according to the 
ATP III criteria.15 
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Data analysis 
Characteristics of pregnancy and cardiovascular risk factors were compared between 
exposed women and non-exposed women in the reference group. For normally 
distributed variables we used an independent t-test and for categorical variables a Chi-
Square test. In the CRP value, which was not normally distributed, we performed a log 
transformation. Values greater than 20 mg/l were excluded from further analysis. We 
conducted ANOVA analysis to adjust the continue measurements for differences in 
age, years postpartum and current smoking. For the differences in development of 
cardiovascular risk factors between both groups we computed odds ratios (OR) with 
95% confidence intervals (95%CI) and used logistic regression analyses to adjust for 
influence of age, years post-partum and current smoking. Data were analysed by using 
SPSS version 16.0 software. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Inclusion and exclusion criteria for PREVFEM cohort. 
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Table 1: Characteristics of the study population at index delivery 
a Significant unadjusted differences (p value < 0.05). 
b Smoking index-pregnancy is defined as smoking on most days during whole pregnancy. 
 
 
 
 
 
RESULTS 
 
A total number of 339 out of 515 invited women (response rate 64%) were willing to 
participate and 332 of 810 non-exposed women (response rate 41%) served as a 
reference group (Figure 1). Characteristics of the index pregnancies for both groups are 
shown in Table 1. Women in the exposed group were approximately 1 year older than 
women in the reference group at delivery with a higher percentage of first pregnancies 
(79.6% and 70.2%, respectively). Amenorrhea duration was significantly shorter in the 
exposed group with lower birth weights and more stillbirths (14.8% and 3.9% 
respectively), reflecting the impact of early preeclampsia on the fetus in the exposed 
group. The occurrence of gestational diabetes mellitus was not different between both 
groups (4.1% for the exposed group and 6.3% for the reference group). Self-reported 
data on family history revealed that gestational hypertension was more frequently 
present in mothers or sisters of the exposed women (39.5%) compared with mothers or 
sisters in the reference group (25.3%, p<0.001), while there were no reported 
differences in family history of gestational diabetes. 
 
 
 
Variable Preeclampsia 
n = 339 
(± SD) 
Non-preeclampsia 
n = 332 
(± SD) 
Age at index partus (years)         29.8 (3.8)        28.6 (4.1) a 
Index pregnancy as first pregnancy (%)         79.6        70.2 a 
Amenorrhea duration (weeks)         31.0 (3.9)        39.6 (2.1) a 
Birthweight index partus (g)     1438 (791)     3408 (647) a 
Stillborn child index-pregnancy (%)         14.8           3.9 a 
Smoking index pregnancyb (%)         11.2         16.6 
Pregnancies (n)           2.7 (1.4)           3.1 (1.4) a 
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Table 2: Characteristics of study population at screening visit outpatient clinic 
a Significant unadjusted differences (p value <0.05). 
 
 
 
Population characteristics at the screening visit in the outpatient clinic are described in 
Table 2. While mean age of participants was comparable between both groups, the 
number of years elapsed since delivery was 16 months less in the exposed group than 
in the reference group (p<0.001). Unadjusted mean systolic (SBP) and diastolic (DBP) 
blood pressures were significantly higher in women after preeclampsia compared with 
women in the reference-group, 127 (SD 17.3) mmHg versus 119 (SD 13.8) mmHg for 
SBP and 86 (SD 11.6) mmHg versus 79 (SD 10.0) mmHg for DBP, respectively, both 
p values <0.001. After adjustment for age, years post index pregnancy and current 
smoking these differences did not change (Table 3). Hypertension was present in 
43.1% of exposed women and in 17.2% of women in the reference group (adjusted OR 
3.59, 95%CI 2.48; 5.20). Only 38% of all women with elevated blood pressure were 
treated with antihypertensive medication. Data on awareness of elevated blood 
pressure, use of antihypertensive medication and control of blood pressure with 
antihypertensive medication are also mentioned in Table 2. Although body mass index 
(BMI) was not significantly different between both groups, obesity (BMI >30 kg/m2) 
was more often present in women after preeclampsia (26.8% vs 20.2%, p=0.04). Waist 
Characteristic Preeclampsia 
n = 339 
Mean (± SD) 
Non-preeclampsia 
n = 332 
Mean (± SD) 
Age (years)       38.9 (4.9)         39.3 (4.4) 
Years post index partus (years)          9.1 (3.7)            10.7 (3.0) a 
Current smoking (%) 15.6 17.5 
Previous smoking (%) 29.5 30.4 
Hypertension (%) 
     Awareness (%) 
     Antihypertensiva (%) 
     Adequate control of women on medication (%) 
43.1 
30.1 
20.6 
38.6 
  17.2a 
    9.0a 
    2.1a 
14.3 
Diabetes Mellitus (%) 
     Oral antidiabetics (%) 
     Insulin (%) 
  2.4 
  0.9 
  0.3 
  1.5 
  0.3 
  0.3 
Hypercholesterolemia (%) 
     Statin use (%) 
38.6 
  1.2 
42.5 
  0.3 
Metabolic syndrome (%) 18.0     9.0 a 
Family history of cardiovascular risk (%) 75.5   63.9a 
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circumference (adjusted), as measure of central obesity, was 86.5 cm in women post 
preeclampsia compared with 83.2 cm in the reference women (p=0.001).  
Fasting levels of glucose, cholesterol, hsCRP and fibrinogen were not significantly 
different between both groups (Table 3). Prevalence and treatment of DM and 
hypercholesterolemia was also not significant different between both groups (Table 2). 
The MetS was more prevalent within women post preeclampsia (18%) compared with 
9% of women with a normal pregnancy in history (adjusted OR 2.18, 95%CI 1.34; 
3.52, p<0.001). 
 
 
 
 
 
Table 3: Adjusted data at screening visit outpatient clinic (adjusted for age; years post index partus 
               and current smoking) 
Risk factor Preeclampsia 
n = 339 
Mean (95%CI) 
Non-preeclampsia 
n = 332 
Mean (95%CI) 
p value 
Systolic blood pressure (mmHg) 127   (125.2; 128.5)  119   (117.6; 121.0) <0.001a 
Diastolic blood pressure (mmHg) 86   (84.4; 86.7) 79    (78.1; 80.4) <0.001a 
Body mass index (kg/m2) 26.9 (26.4; 27.5) 26.2 (25.5; 26.7)   0.066 
Waist circumference (cm) 86.5 (85.2; 87.8) 83.2 (81.9; 84.5)   0.001a 
Total cholesterol (mmol/l) 4.86 (4.78; 4.95) 4.85 (4.76; 4.94)   0.85 
LDL (mmol/l) 2.89 (2.81; 2.98) 2.90 (2.81; 2.98)   0.95 
HDL (mmol/l) 1.52 (1.48; 1.56) 1.53 (1.49; 1.57)   0.77 
Triglycerides (mmol/l) 1.00 (0.95; 1.06) 0.95 (0.89; 1.06)   0.18 
Ratio HDL/total cholesterol 3.40 (3.29; 3.51) 3.35 (3.23; 3.46)   0.54 
Glucose (mmol/l) 4.86 (4.76; 4.95) 4.85 (4.75; 4.94)   0.92 
HbA1c (%) 5.27 (5.22; 5.31) 4.24 (5.19; 5.28)   0.37 
CRP (mg/l) b  3.55 (3.05; 4.05) 3.19 (2.68; 3.69)   0.33 
CRP log transformation 0.79 (0.69; 0.88) 0.74 (0.66; 0.84)   0.57 
Fibrinogen (g/l) 2.85 (2.79; 2.92) 2.84 (2.77; 2.91)   0.75 
    
 OR (95%CI) OR (95%CI)  
Hypertension 3.59 (2.48; 5.20) 1.0 <0.001a 
Diabetes Mellitus 1.72 (0.54; 5.48) 1.0   0.36 
Hypercholesterolemia 0.94 (0.68; 1.30) 1.0   0.70 
Metabolic syndrome 2.18 (1.34; 3.52) 1.0   0.002 a 
aSignificant differences p value <0.05. 
bCRP values >20 mg/l excluded. 
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DISCUSSION 
 
In this study we found a prevalence of hypertension (adjusted OR 3.59) before the age 
of 40 years over three times higher in women with previous early preeclampsia in 
comparison with an age-matched reference group after uncomplicated pregnancy. Less 
than half of these hypertensive women were treated adequately with anti-hypertensive 
medication. Although hypercholesterolemia (total cholesterol >5.0 mmol/l or use of 
statins) could be demonstrated in almost 40% of women, we found no differences in 
the prevalence of hypercholesterolemia or diabetes between both groups and the use of 
statins and antidiabetic medication was comparable. Other studies have shown more 
unfavorable levels of lipids and glucose in women post preeclampsia. However, in the 
study of Berends et al. significant differences for glucose and blood pressure were 
found, but not for lipids.16 In this study women with a mean of 7 years post index 
pregnancy were included while in other studies, which found differences in lipids as 
well, women were 16-17 years post partum.17-18 As lipid levels rise gradually in 
relation to alterations in hormonal status in women during middle-age, and menopausal 
transition induces an accelerated increase of lipids this could be an explanation for the 
lack of abnormalities in lipids within our still relatively young group of females.19  
MetS was twice more prevalent in exposed women as in the reference group, 
respectively 18% and 9%. As the MetS is a frequently occurring consequence of 
obesity it has important implications for the development of future CVD.20 The 
relatively high occurrence of the MetS in our study population was merely driven by 
hypertension and central obesity. After adjustment for hypertension and waist 
circumference the OR for the development of the MetS in women post early 
preeclampsia was no longer significant. As it was shown in the Framingham Offspring 
study the trajectory of entering the MetS with hypertension and central obesity confers 
a high risk for future CVD, especially in women.21 The elevated waist ratios in exposed 
women demonstrate a known correlation between central fat distribution and 
hypertension.22 In the EPIC-Norfolk study a linear increase of blood pressure (SBP and 
DBP) across the range of waist-hip ratio in both men and women was found, whereas 
waist circumference per se was also independently of differences in age and BMI 
related to SBP and DBP in females.23 Both BMI and waist circumference are predictive 
of fatal and non-fatal CVD risk.24 Obesity-related hypertension may be more resistant 
to medical treatment than hypertension with normal weight. Lifestyle changes are the 
primary important preventive measures in obesity-related hypertension.25  
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In our present study we found that almost 76% of exposed women had a positive 
family history for CVD, compared with 64% of non-exposed women (p=0.006). As 
family history was assessed by questionnaire it may contain uncertainties. It is 
currently still debated whether hypertensive disorders in pregnancy alone lead to a 
higher susceptibility for CVD risk or whether a common genetic predisposition is 
causative for both the metabolic disturbances during pregnancy and the elevated CVD 
risk.26,27 Romundsen et al. found higher pre-pregnancy levels of blood pressure and 
BMI in women who developed preeclampsia or gestational hypertension compared 
with women with non-hypertensive pregnancies.28 Although their cohort consisted of a 
heterogeneous group of women after gestational hypertension as well as women with 
early and late preeclampsia, they suggest a relation between pre-pregnancy 
cardiovascular risk factors and future CVD risk. A limitation of our study is that we 
had no data on pre-pregnancy values of blood pressure, BMI and waist/hip 
measurements. In the questionnaire at the outpatient clinic 5% of exposed women and 
7.5% of women from the reference group reported hypertension before index 
pregnancy. However, with these data we cannot reject or confirm a relation between 
pre-pregnancy hypertension and current hypertension.  
It has been suggested that early and late preeclampsia may represent heterogeneous 
expressions of one common disease, while others assume a different pathophysiology 
of both conditions.12,29,30 While early preeclampsia may be caused by severe placental 
dysfunction through impairment of trophoblast invasion, placental damage in late-onset 
preeclampsia is less severe with fewer maternal consequences. The timing of the onset 
of preeclampsia may therefore interfere with long-term consequences of maternal 
health. In a retrospective cohort study Stekkinger et al. found a higher incidence of the 
MetS in women with a history of early-onset preeclampsia (delivery before 32 weeks) 
compared with women after late-onset preeclampsia (delivery at/beyond 32 weeks) at 
36-52 weeks post index-delivery.31 In our study we included only women after early 
preeclampsia (symptoms and delivery before 32 weeks of gestation). Therefore, as a 
limitation of our study we cannot extrapolate our findings to all women with 
preeclampsia. Another limitation is the use of the obstetric database of our hospital to 
establish the reference cohort. In The Netherlands about 30-35% of uncomplicated 
pregnancies were delivered at home during our time period, indicating that our 
reference group may contain higher risk pregnancies that were referred to hospitals.32 
Further, differences in response rate of participants within our study groups arouse 
concern. Bias may have been introduced by the higher response rate for participation in 
the exposed group than in the reference group (64% vs 41%). Despite our repeated 
efforts with letters and telephone calls, women in the reference group were less 
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motivated than exposed women to take a day off and to travel to our outpatient clinic. 
Young women after serious health problems in pregnancy had a higher concern for 
future disease risk than women with uncomplicated pregnancies.  
 
 
CONCLUSION 
 
Women after early preeclampsia have a 3.59 times higher risk of hypertension and a 
2.18 times higher risk for development of the metabolic syndrome in women post early 
preeclampsia at 10 years post index pregnancy. The aetiology of preeclampsia is yet 
unresolved. Research on genetics and metabolic biomarkers is needed for a better 
understanding of its pathogenesis.33 Additional research should focus on the cost-
effectiveness of cardiovascular screening programs and the timing of treatment of 
cardiovascular risk factors in women with previous preeclampsia. Further, 
identification of subsets of patients at higher risk is needed. 
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ABSTRACT 
 
Objective: Women with a history of preeclampsia are at increased risk to develop 
cardiovascular disease (CVD) later in life, especially hypertension is common. In this 
study we aimed to evaluate electrocardiographic parameters as a proxy for detrimental 
hypertensive effects and later CVD. 
Methods: The Preeclampsia Risk EValuation study in FEMales (PREVFEM) study is a 
prospective cohort study consisting of 339 women with a history of early-onset pre-
eclampsia (EOP) and 332 age-matched women without a history if EOP as reference. 
At 10 years post index pregnancy a 12-lead electrocardiogram recording was made. 
Results: There were no significant differences in ECG parameters between both groups 
at 39 years of age. In our cohort of young women SBP (ORmmHg 1.04; 95%CI 1.2; 
1.06) as well as DBP (ORmmHg 1.04; 95%CI 1.01; 1.07) and stage 2 hypertension (OR 
3.35; 95%CI 1.16; 9.63) were significantly associated with ECG criteria for LVH, but 
not for other ECG abnormalities. EOP gives no significant adjusted risk on ECG 
abnormalities compared to women without EOP.  
Conclusion: EOP is no significant predictor of non-specific ECG abnormalities. 
Routine ECG screening in young women after preeclampsia is not recommended in 
non-hypertensive women, but may be useful when hypertension is present. 
 
 
INTRODUCTION 
 
Women with a history of hypertensive pregnancy disorders are at increased risk to 
develop cardiovascular disease (CVD) later in life. Meta-analyses of population-based 
studies have shown that in women with a history of preeclampsia, defined as 
hypertension with proteinuria, CVD risk is more than two times higher than in 
unaffected women.1-3 In the latest guidelines from the American Heart Association on 
CVD prevention in women, careful monitoring of cardiovascular risk factors in this 
subset of women at elevated risk is recommended.4 However, validated tools to assess 
the future cardiovascular risk in these young women are yet not available. First signs of 
increased CV risk in women after preeclampsia are elevated systolic (SBP) and 
diastolic (DPB) blood pressures and a higher prevalence of hypertension compared to 
women with uncomplicated pregnancies.5 Several studies have identified electro-
cardiographic (ECG) screening as an adequate tool to improve risk prediction in 
hypertensive populations.6,7 Prognostic ECG abnormalities in hypertensive patients are 
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voltage-criteria of left ventricular hypertrophy (LVH) and repolarization abnor-
malities.8,9 
In population-based studies non-specific ECG changes have also been shown to be 
important in evaluating future CVD morbidity and mortality.10-18 The frontal T axis 
reflects abnormalities in ventricular repolarization and a deviated T axis may be an 
important predictor of cardiovascular risk.11,12,16 The spatial QRS-T angle reflects both 
depolarisation and repolarization and is an even stronger predictor of future CVD 
events, whereas a wider angle is associated with a higher risk of CVD events (coronary 
heart disease, congestive heart failure and mortality).11,17-19 Methods to derive the 
spatial QRS-T angle are not widely available as it requires vector transformation of the 
12-lead ECG. The frontal QRS and T axis are available in most electrocardiographic 
ECG reports and are often used in clinical practice as a suitable substitute for the 
spatial QRS-T angle.10  
Thus far, only one study has evaluated the presence of ECG abnormalities in women 
with a history of early and late preeclampsia. In 443 women after previous 
preeclampsia, at a mean age of 60 years the presence of any ECG abnormalities, 
according to the Minnesota code, was two times higher in comparison with a control 
group (adjusted odds ratio (OR) 1.96, 95%CI 0.96; 2.98).20 It is not known however at 
which age first signs of ECG abnormalities appear in females after hypertensive 
pregnancy disorders and if standard ECGs are useful in this target population. The 
objective of our study therefore is to identify ECG changes related to elevated blood 
pressure in women 40 years of age and to evaluate the effect of early-onset 
preeclampsia (EOP) in females on the identified ECG changes.  
 
 
METHODS 
 
Population 
Since 1991 the obstetric department of the Isala klinieken in Zwolle, The Netherlands, 
registers all in-hospital deliveries. We invited consecutively all women registered as 
having had EOP (n=528) as well as an equal number of age-matched females with a 
non-hypertensive, uncomplicated, pregnancy during the same time-period (1991-2007) 
to participate in the Preeclampsia Risk EValuation in FEMales (PREVFEM) cohort 
study. This study was set up to evaluate the presence of cardiovascular risk factors in 
young women 10 years post pregnancy complicated by EOP. Early preeclampsia was 
defined as an elevated diastolic blood pressure >90 mmHg with proteinuria (>0.3 g/24 
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h) between 20 and 32 weeks of gestation. Approval for the study was obtained from the 
institutional review board of the Isala klinieken in Zwolle. Participants were included 
in the study after signing an informed consent form and were invited for a 
cardiovascular screening program at the Department of Cardiology on average after 10 
years post index pregnancy. The detailed protocol of the screenings procedure has been 
described elsewhere, as well as the used definitions of cardiovascular risk factors.5 
 
ECG analysis and interpretation 
A standard 12-lead electrocardiogram was recorded in lying position using Welch 
Allyn CardioPerfect equipment and ECGs were stored digitally. With CardioPerfect 
software ECG measurements were computed for a representative averaged beat for 
each of the 12 different leads. Welch Allyn Cardioperfect provides data on conduction 
(ms); amplitude (μV); frontal P, QRS and T axis (°); ST segment and T wave deviation 
(μV) and heart rate (bpm).  
The Minnesota Code (MC) Classification System for Electrocardiographic Findings 
was used to define ECG abnormalities.21 Major repolarization abnormalities were 
coded as ST deviation according to MC 4-1-1, 4-1-2 and 4-2 or negative T wave coded 
as 5-1 and 5-2. Minor repolarization abnormalities were coded as MC 4-3 and 5-3. Left 
ventricular hypertrophy (LVH) was assessed by presence of either the gender-specific 
Cornell product (R aVL + S V3 >2.0 mV in women) or the Solokow-Lyon voltage 
criteria (S V1 + R V5/V6 >38 mm). Frontal T axis and frontal QRS-T angle were 
divided in two classes, normal and abnormal. Normal T axis was defined as 25-65° and 
normal frontal QRS-T angle was defined as an angle between 0 and 90°.13,14,16 
 
Data analysis 
Participant characteristics at the screening visit were described for women with and 
without EOP at baseline using means and standard deviations for continuous normally 
distributed variables and frequencies and percentages for categorical variables.  
To evaluate the effect of blood pressure on different ECG abnormalities, we performed 
logistic regression analyses per unit of increment arterial blood pressure to compute 
odds ratios (OR) with 95% confidence intervals (95%CI) in all women, and to adjust 
for potential confounders (age, current smoking and waist circumference). Blood 
pressure was classified into four categories according to the Joint National Committee 
report 7.22 Different categories were normal blood pressure (SBP <120 mmHg and 
DBP <80 mmHg); prehypertension (SBP 120-139 mmHg or DBP 80-89 mmHg); stage 
1 hypertension (SBP 140-159 mmHg or DBP 90-99 mmHg); stage 2 hypertension 
(SBP >160 mmHg or DBP >100 mmHg). Women on antihypertensive medication were 
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classified in ‘stage 2 hypertension’. Odds ratios (95%CI) on the ECG abnormalities 
were computed for all hypertension categories, whereas ‘normal blood pressure’ served 
as the reference category.  
To quantify the effect of EOP on development of ECG abnormalities between both 
cohort groups we reported ECG abnormalities as percentage in both groups, 
differences in prevalence between both groups were tested with Chi-Square test or 
Fisher’s exact test. Finally, we calculated OR (95%CI) on development of ECG 
abnormalities in women with history of EOP. Women without history of EOP served 
as reference. Adjustments were done for age, current smoking and waist 
circumference. Data were analysed by using SPSS version 16.0 software. 
 
 
RESULTS 
 
A total number of 671 women were included in the PREVFEM- study, 339 in the EOP 
group (response rate 64%) and 332 in the reference group (response rate 41%). 
Baseline characteristics of women are shown in Table 1. Mean age of participants in 
both groups was 39 years and they were on average 10 years post index-pregnancy. As 
described elsewhere SBP was 127 mmHg in women with history of EOP and 119 
mmHg for women without (p<0.05) and DBP was 86 mmHg and 79 mmHg, 
respectively (p<0.05). Hypertension was significant more prevalent in women with 
history of EOP compared to the reference groups (43% versus 17%, p<0.05) and this 
difference remained significant after adjustment for potential confounders.5 Of all 
participants an ECG at baseline visit was available for analysis. Mean heart rate was 70 
±12.6 bpm and abnormal ECG parameters were present in both groups, although only 
in a small percentage of women (Table 1). Presence of LVH was equal in women with 
history of EOP (6%) in comparison with women without EOP (5%), p value 0.64. 
Analysis of blood pressure as continuous variable and ECG characteristics in all 671 
women shows significantly increased risk of the presence of LVH for raised SBP 
(ORmmHg 1.04; 95%CI 1.02; 1.06) and raised DBP (ORmmHg 1.04; 95%CI 1.01; 1.07). 
After adjustment for age, smoking and waist these data remain unchanged. Other ECG 
characteristics were non-significant. Table 2 shows the OR for the different stages of 
hypertension on the presence of ECG abnormalities. Only stage 2 hypertension (SBP 
>160 mmHg or DBP >100 mmHg or use of antihypertensive medication) was 
associated with a significantly increased risk of presence of LVH, after adjustment for 
confounders (OR 3.35 (95%CI 1.16; 9.63).  
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Table 1: Characteristics of study population at cardiovascular screenings visit  
 
Characteristic Preeclampsia 
n = 339 
mean (±SD) 
Non-preeclampsia 
n = 332 
mean (±SD) 
Age (years)       38.9 (4.9)       39.3 (4.4) 
Years post index partus (years)         9.1 (3.7)       10.7 (3.0)a 
Current smoking (%)       15.6       17.5 
Systolic blood pressure (mmHg)   127 (17.3)     119 (13.8)a 
Diastolic blood pressure (mmHg)     86 (11.6)       79 (10.0)a 
Body mass index (kg/m2)     26.9 (5.7)       26.2 (4.9) 
Waist circumference (cm)     86.6 (14.2)       83.4 (10.7)a 
Total cholesterol (mmol/l)       4.8 (0.8)         4.9 (0.8) 
LDL (mmol/l)       2.9 (0.8)         2.9 (0.8) 
HDL (mmol/l)       1.5 (0.4)         1.5 (0.3) 
Triglycerides (mmol/l)       1.0 (0.5)         0.9 (0.5) 
Ratio HDL/total cholesterol       3.4 (1.0)         3.4 (1.0) 
Glucose (mmol/l)       4.9 (1.1)         4.8 (0.6) 
Hypertension (%)     43.1       17.2a 
Diabetes mellitus (%)       3.5         2.1 
Hypercholesterolemia (%)     38.6       42.5 
Metabolic syndrome (%)     18.0         9.0a 
ECG parameters   
Heart rate (bpm)     69.8 (12.1)       70.4 (13.2) 
Abnormal T axis (%)     21.5       19.6 
Abnormal frontal QRS-T angle (%)       2.1         3.9 
Major repolarization abnormalities (%)       6.8         6.6 
Minor repolarization abnormalities (%)     31.3       34.6 
LVH (%) Cornell or Solokow       5.7         4.9 
aSignificant unadjusted differences (p value <0.05). 
 
 
 
 
 
OR for development of different ECG abnormalities in women with history of EOP 
compared to women without history of EOP were all non-significant (adjusted for age, 
smoking and waist).  
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DISCUSSION 
 
To the best of our knowledge, this is the first study to evaluate the prevalence of ECG 
abnormalities in young women, mean age 39 years, with a history of early 
preeclampsia. We found no significant differences in the occurrence of ECG 
abnormalities in women at 10 years post preeclampsia in comparison with similar aged 
women after uncomplicated pregnancy.  
However, we confirmed a significant relation between continuous level of both SBP 
(OR 1.04; 95%CI 1.2; 1.06) and DBP (OR 1.04; 95%CI 1.01; 1.07) with ECG criteria 
for LVH. Within different stages of hypertension only stage 2 hypertension (SBP ≥160 
mmHg or DBP ≥100 mmHg or the use of antihypertensive medication) was predictive 
for LVH criteria (OR 3.35 (95%CI 1.16; 9.63).  
Although hypertension (SBP ≥140 mmHg or DBP ≥90 mmHg or use of 
antihypertensive medication) is the most frequent occurring early risk factor after 
preeclampsia and already present in 43% of EOP women before the age of 40 years in 
the PREFVEM-study, first signs of electrocardiographic parameters for LVH are yet 
uncommon at this age (5.7%). Even in elderly women in the raloxifen use for the heart 
(RUTH) study (mean age 68 years), criteria for LVH on ECG recordings were met in 
only 35% of the large proportion (78%) of participating hypertensive women.23 The 
sensitivity of ECG criteria for LVH is therefore low to detect detrimental effects of 
hypertension, although its specificity is high.24 In young women the premenopausal 
estrogens status prohibits the development of LVH, while after menopause progression 
to LVH occurs more frequently.25 This may also be an explanation for the low 
occurrence of electrocardiographic signs of LVH in our study. Non-specific ECG 
abnormalities are yet uncommon in previously affected EOP women at the age of 40 
years. Most studies on prognostic value of ECG criteria in the development of CVD 
have been undertaken in populations that were older (between 48 and 75 years).12-15,20 
However, our study showed that even young females with stage 2 hypertension (SBP 
≥160 mmHg or DBP ≥100 mmHg or use of antihypertensive medication) are at 
increased risk for electrocardiographic criteria for LVH (OR 3.41, 95%CI 1.10; 10.60; 
p value 0.03) compared to young women with normal blood pressures. As ECG 
recordings are currently easily available in primary health care they should be part of 
the routine assessment in all subjects with high blood pressure according to the 
European guidelines on arterial hypertension.26  
One of the limitations of our study is the use of the frontal QRS-T angle instead of the 
spatial QRS-T angle, as the evidence on use of the frontal angle as a substitute for the 
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spatial angle is limited.10 To define an abnormal frontal T axis we used the definition of 
Atsma et al.16 Others have applied different criteria for defining categories of normal 
and abnormal T axis, but small changes of thresholds did not essentially change their 
results.12 Another limitation is the use of electrocardiographic criteria for LVH. A 
recent review concluded that ECG criteria cannot rule out LVH.27 Further research 
with echocardiographic data of LVH in young women post preeclampsia is 
recommended. 
In conclusion, we do not recommend routine ECG assessment for CVD risk prediction 
in young non-hypertensive women after EOP. In young females, however, with grade 2 
hypertension, ECG recordings are useful to detect early signs of LVH.  
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ABSTRACT 
 
Women with a history of preeclampsia are at increased risk for future cardiovascular 
disease. Determination of cardiovascular biomarkers may be useful to understand the 
pathophysiological mechanism of cardiovascular disease development in these women. 
We performed an analysis in the Preeclampsia Risk EValuation in FEMales study 
(PREVFEM), a retrospective cohort consisting of 339 women with a history of early 
preeclampsia and 332 women after normotensive pregnancy, who attended a follow-up 
visit 10 years after the index pregnancy. A subset of eight different cardiovascular 
biomarkers was investigated, reflecting inflammatory, metabolic, thrombotic and 
endothelial function markers. Associations between PE and these novel biomarkers 
were analyzed by linear regression analysis and adjusted for traditional cardiovascular 
risk factors. 
Mean age of 671 women of the PREVFEM cohort was 39 years and women were on 
average 10 years post index pregnancy. Women post preeclampsia had significantly 
higher levels of SE-selectin (adjusted difference 4.55, 99%CI 0.37; 8.74) and PAPPA 
(adjusted difference 19.08; 99%CI 13.18; 24.99), whereas ApoB (adjusted difference   
-0.23 99%CI -0.32; -0.14) was inversely associated with preeclampsia, compared to 
women with a previous normotensive pregnancy. Adiponectin, leptin, sICAM-1, 
sVCAM-1 and PAI-1 were not different between both groups. 
In this retrospective cohort analysis we demonstrated an independent association of 
preeclampsia with SE-selectin and PAPPA (markers of vascular dysfunction), which 
may contribute to future cardiovascular events in women post preeclampsia. However, 
ApoB (a lipoprotein) was significantly lower and could point at a protective 
mechanism in our PE study women. 
 
 
INTRODUCTION 
 
Hypertensive disorders of pregnancy (HPD), like gestational hypertension (GH) and 
preeclampsia (PE), occur in about 10% of pregnancies.1,2 These syndromes  have 
important consequences for maternal health during pregnancy and the postpartum 
period, but also for future cardiovascular disease (CVD) risk.3-5 Dependent on the type 
of HPD, the risk of future CVD is 1.4-3.0 times higher in women with a history of 
HPD compared to women with previous normotensive pregnancies .6  The severity and 
timing of HPD importantly determines the impact of long-term CVD risk, with early 
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PE as one of the most hazardous conditions.3,7 The increased CVD  risk in women with 
a history of PE can be partly attributed to the increased prevalence of classic CVD  risk 
factors like hypertension, hypercholesterolemia and the metabolic syndrome (MetS).8-10 
Although the underlying pathophysiological mechanism of the increased prevalence of 
cardiovascular risk factors in these women is not completely understood, endothelial 
dysfunction seems to play an important role, although not consistently.11,12 Novel 
genetic evidence indicates potentially shared mechanisms of both preeclampsia and 
CVD, in particular for oxidative stress and inflammation.13 
In the last decade(s) several novel biomarkers associated with CVD have been 
identified.14,15 Some of these biomarkers, like cytokines (e.g. interleukins); angiogenic 
factors (endoglin); cell adhesion molecules (soluble fms-like tyrosine kinase 1) and 
coagulation factors (plasminogen activator inhibitor, PAI-1), are upregulated during 
preeclamptic pregnancies.16-18 Data of these novel biomarkers in young women with a 
history of preeclampsia may unravel the pathophysiological mechanisms of the 
increased CVD risk in these women. However, study data on biomarkers in this subset 
of females are not consistent. Sattar et al. found increased levels of intercellular 
adhesion molecule (ICAM) in women post PE; however, no differences in lipids, 
vascular cellular adhesion molecule (VCAM), E-selectin and leptin were reported.11 In 
the study of Girouard et al. it was shown that women with a history of PE and GH, 
have significant differences in lipid profile and several miscellaneous markers (TNF-α, 
Interleukin-6, leptin, adiponectin and homocysteine) at 8 years post index pregnancy 
compared with control subjects.19 Wolf et al. demonstrated increased levels of soluble 
fms-like tyrosine kinase and insulin resistance in women after  PE compared to women 
with normotensive pregnancies within 18 months postpartum.20 However, several other 
studies did not find any differences in biomarker profiles between women with and 
without a history of HPD.21-23  
In this retrospective cohort study we measured levels of various novel cardiovascular 
biomarkers in women with and without prior preeclampsia and adjusted the 
associations for traditional cardiovascular risk markers. Of the many available 
biomarkers we selected apolipoprotein B (ApoB), a lipid-associated marker, and leptin 
and adiponectin as cardiometabolic risk markers. We also studied the following 
endothelial function markers: soluble intercellular adhesion molecule (sICAM-1), 
soluble vascular adhesion molecule (sVCAM-1), soluble endothelial selectin (SE 
selectin), and a thrombotic marker, plasminogen activator inhibitor (PAI-1). 
Furthermore, we evaluated pregnancy associated plasma protein A (PAPPA), a 
metalloproteinase, which is associated with vulnerable atherosclerotic plaques.24   
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METHODS 
 
Population 
Since 1991, the obstetric department of the Isala klinieken in Zwolle, The Netherlands, 
has registered all in-hospital deliveries. We invited consecutively all women registered 
as having had early-onset preeclampsia, n=528, in the time period (1991-2007) to 
participate in the Preeclampsia Risk EValuation in FEMales (PREVFEM) cohort-
study. For the reference group we invited an equal number of age-matched females 
with a non-hypertensive, uncomplicated, pregnancy during the same period. They were 
selected from the obstetric database after selection based on age and date of delivery, 
and aiming for an equal distribution of these two variables (range ±2 years).  
The study was initiated to evaluate the presence of cardiovascular risk factors in young 
women at 10 years post pregnancy complicated by early-onset PE. This was defined as 
an elevated diastolic blood pressure >90 mmHg with proteinuria (>0.3 g/24 h) between 
20 and 32 weeks of gestation. Approval for the study was obtained from the 
institutional review board of the Isala klinieken in Zwolle. Participants were included 
in the study after signing an informed consent form and were invited for a 
cardiovascular screening program at the Department of Cardiology. The protocol, 
definitions of cardiovascular risk factors and baseline data have been described 
elsewhere.10  
 
Biomarker analysis 
At the scheduled screening visit an overnight fasting venous blood sample was taken. 
Blood lipid profile, glucose, CRP and fibrinogen were locally analyzed and the results 
have been described previously.10 
Assessment of all novel biomarkers was performed at the laboratory of experimental 
medicine, at the department of Internal Medicine, Radboud University Medical Center, 
Nijmegen, The Netherlands. All markers were analysed with a Luminex assay, a multi-
analyte technology, based on the principles of flow cytometry.25 As a consequence of 
the use of a multi-assay kit, some samples were out of the detection range, for sICAM-
1 the lower detection level was 8 ng/ml (n=1 out of range), for PAPPA the lower limit 
was 0.69 ng/ml (n=28) and for leptin the lower limit was 0.8 ng/ml (n=2). These values 
were fixed at the lower detection level.  
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Data analysis 
Baseline characteristics were expressed as mean (SD) or number (percentage). 
Biomarker levels were expressed as continuous variables, mean with SD. Differences 
in variables between women with and without PE for continuous data were analysed by 
Student’s t-test for independent groups and for categorical data with Chi-square or 
Fisher exact test. Univariate analysis was performed with a two-sided probability value 
of <0.05.  
Association between PE and biomarkers was analysed using linear regression analysis 
and stepwise adjusted according to four different models. Model 1 adjusted for age; 
model 2 for age, years postpartum and smoking; model 3 included the variables of 
model 2 and presence of hypertension; and in model 4 we added the presence of MetS 
(dichotomous) to the aforementioned variables. Data were expressed as the differences 
(β) in biomarkers of women with a history of PE compared to the reference women, 
with 99% confidence interval (99%CI). All p values were two-sided.  
As levels of the different biomarkers were not normally distributed (according to the 
Kolmogorov-Smirnov test), we additionally performed a natural log transformation on 
the biomarkers and repeated the above-mentioned analysis. Since the results of these 
natural log transformed analyses did not differ from the original analysis, we prefer to 
present the original untransformed data to facilitate interpretation of our data in clinical 
use.  
Data analyses were performed with SPSS software version16.0. 
 
 
RESULTS 
 
A total number of 671 women were included in the PREVFEM-study, 339 in the early-
onset PE group and 332 in the reference group. Mean age of participants in the cohort 
was 39 years and women were on average 10 years post index-pregnancy. Baseline 
characteristics of the PREVFEM-cohort have been described elsewhere.10 
Hypertension was more prevalent in women post PE (43%) than in reference women 
(17%), as was the MetS (18% in PE women versus 9% in reference women). 
Prevalence of diabetes mellitus, levels of different lipid markers and levels of the 
inflammatory markers (CRP and fibrinogen) were not different between both groups 
(Table 1). 
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Table 1: Characteristics of study population at cardiovascular screenings visit  
Characteristics Early preeclampsia 
n = 339 
Mean (±SD) 
Reference 
n = 332 
Mean (±SD) 
Age (years)         38.9 (4.9)             39.3 (4.4) 
Years post index partus (years)           9.1 (3.7)             10.7 (3.0) a 
Current smoking (%)         15.6             17.5 
Systolic blood pressure (mmHg)       127 (17.3)           119 (13.8) a 
Diastolic blood pressure (mmHg)         86 (11.6)             79 (10.0) a 
Hypertension (%)         43.1             16.7    a 
Body Mass Index (kg/m2)         26.9 (5.7)             26.2 (4.9) 
Waist circumference (cm)         86.6 (14.2)             83.4 (10.7)   a 
Total cholesterol (mmol/l)           4.8 (0.8)               4.9 (0.8) 
LDL cholesterol (mmol/l)           2.9 (0.8)               2.9 (0.8) 
HDLcholesterol (mmol/l)           1.5 (0.4)               1.5 (0.3) 
Triglycerides (mmol/l)           1.0 (0.5)               0.9 (0.5) 
Ratio HDL/total cholesterol           3.4 (1.0)               3.4 (1.0) 
CRP (mg/l) b           3.6 (5.4)               3.1 (3.8) 
Fibrinogen (g/l)           2.9 (0.6)               2.8 (0.6) 
Glucose (mmol/l)           4.9 (1.1)               4.8 (0.6) 
Diabetes mellitus (%)           1.2               0.6 
Metabolic syndrome (%)         18.0               9.1a 
a Significant unadjusted differences (p value <0.05). 
b CRP values >20 mg/l excluded. 
 
 
 
 
Table 2: Mean biomarker levels according to history of early-onset preeclampsia  
Biomarker Early preeclampsia 
n= 339 
Mean (SD) 
Reference  
n = 329 
Mean (SD) 
Adiponectin (µg/ml) 57.9 (36.8) 57.7 (36.1) 
PAI-1 (ng/ml) 27.2 (16.6) 27.1 (16.4) 
Leptin (ng/ml) 26.3 (19.5) 24.2 (17.9) 
sICAM-1 (ng/ml) 94.2 (69.5)  105.6 (63.4)  a           
sVCAM-1 (ng/ml) 910.0 (176.2) 907.0 (173.0) 
SEselectin (ng/ml) 48.9 (22.3)       45.3 (18.5)    a            
PAPPA (ng/ml) 38.7 (32.2)      22.5 (23.2)   a           
ApoB (g/l) 0.92 (0.30)         1.15 (0.52)   a           
a Significant unadjusted differences (p value < 0.05). 
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Blood samples for biomarker analysis were unavailable for three women in the 
reference group. Table 2 shows levels of biomarkers in women with PE and the 
reference group. In Table 3 we describe the adjusted differences in biomarkers for 
women with a history of PE compared to women with a history of uncomplicated 
pregnancy (reference group). After adjustment for traditional cardiovascular risk 
factors, women with PE had significantly higher levels of SE-selectin (β 4.55, 99%CI 
0.37; 8.74) and PAPPA (β 19.08, 99% CI 13.18; 24.99) compared to women with a 
healthy pregnancy. Levels of ApoB were significant lower for women post PE 
compared to reference women, also after adjustment for traditional CVD risk factors 
(smoking, hypertension, MetS (model 4)), adjusted difference β -0.23, 99%CI -0.31;    
-0.14. Levels of sICAM-1 were lower in PE women (94.2, SD 69.5 ng/ml) compared to 
reference women (105.6, SD 63.4 ng/ml) at crude analysis (p<0.05); however, after 
multiple adjustment with a probability level of 0.01, results attenuated to non-
significant (β -13.92, 99%CI -28.12; 0.28). In accordance with the crude results, 
adjustment for potential confounders did not show any significant association between 
PE and consecutively adiponectin (β 1.65, 99%CI -6.02; 9.32), leptin (β -0.26, 99%CI   
-4.05; 3.52), sVCAM-1 (β 6.56, 99%CI -30.71; 43.82) and PAI-1 (β -2.97, 99%CI        
-6.22; 0.29). 
 
DISCUSSION 
 
In this cross-sectional analysis of the PREVFEM study, we evaluated the associations 
between various novel CVD biomarkers in women with and without a history of PE. 
Our data show that women 10 years after PE have higher levels of SE-selectin and 
PAPPA compared to women without previous PE, after adjustment for traditional CV 
risk factors (smoking, hypertension, MetS). The increased levels of SE-selectin and 
PAPPA may contribute to the higher cardiovascular risk in these women.3-5  
SE-selectin, a marker of endothelial dysfunction, is associated with an increased risk of 
type 2 diabetes mellitus, but higher levels are also related to CVD events.26,27 The 
elevated  levels of SE-selectin in our cohort of women, 10 years after PE, may be an 
expression of (persistent) endothelial dysfunction. In contrast with our results, other 
studies like those of Sattar et al. and Gaugler-Senden et al. could not demonstrate 
increased levels of SE-selectin in women post PE.11,21 One of the explanations of this 
inconsistency may be the heterogeneity of included participants in different studies. 
Whereas in our cohort only women with early-onset PE were included, Sattar et al.11 
investigated the whole spectrum of PE. Gaugler-Senden et al. did also include women 
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with severe and early-onset preeclampsia, but their cohort was very small (n=16), 
limiting the power to detect an association.21 In addition, both studies did not correct 
for the potential influence of traditional cardiovascular risk factors on biomarker levels, 
which might explain another part of the inconsistency between data. 
Pregnancy-associated plasma protein A (PAPPA) is a metalloproteinase which is 
associated with the presence of vulnerable atherosclerotic plaques.24 Elevated levels of 
PAPPA and other metalloproteinases during pregnancy have been shown to be 
associated with worse obstetric outcomes and risk of PE.28,29 Metalloproteinases may 
be the link between placental alterations in pregnancy and harmful cardiovascular 
effects later in life as increased levels of PAPPA are also associated with risk of 
(recurrent) acute coronary syndromes.30-32 We therefore hypothesize that the vascular 
alterations in PE lead to persistent vascular damage and early development of 
vulnerable atherosclerotic plaques, as shown by increased levels of PAPPA in women 
post PE. This can subsequently contribute to premature cardiovascular events. 
One of the other remarkable results in our study was the lower levels of ApoB in 
women post PE compared to reference. ApoB is a very potent cardiovascular risk 
marker and these lower levels suggest protection against future CV events for women 
post PE.33 We do not understand the pathophysiological mechanism of the decreased 
levels of ApoB. As LDL-cholesterol and triglyceride levels do not differ and 90% of 
ApoB is associated with LDL particles33, the lower ApoB levels in women post PE 
suggest the presence of large, buoyant LDL particles, which are associated with 
decreased cardiovascular risk. On the other hand, the study of Girouard et al. 
demonstrates increased levels of ApoB for both women with a history of GH and PE 
compared to control subjects.19 We do know that hormonal factors, like use of oral 
anticonceptiva and postmenopausal status, can increase levels of ApoB.34,35 However,  
the same is true for LDL cholesterol34,35, in which we did not find a difference between 
PE and reference women. Besides, postmenopausal status and length of hormonal 
anticonceptive use was equal in both groups of our cohort. But current oral 
anticonceptive use is higher in reference women (40%) compared to former 
preeclamptic women (31%), additional adjustment for current use of oral 
anticonceptiva did not change the ApoB results in our study. 
All other biomarkers, including the previously measured CRP and fibrinogen, did not 
show any difference between women with and without a history of PE. This is 
consistent with several other studies21-23, with the exception that Sattar et al.11 did 
demonstrate increased levels of s-ICAM1 in women post PE and Girouard et al.19 
demonstrated significant differences in leptin, adiponectin and CRP in a combined 
cohort of GH and PE. Considering the conflicting results in literature, mechanistic 
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studies are necessary to explain the associations between different endothelial 
dysfunction biomarkers and PE. 
 
Strengths and limitations 
Studies on the levels of CVD biomarkers in women after PE are relatively scarce and 
inconsistent.11,19-23 An important reason for this inconsistency is the heterogeneity of 
the included patients in the studies, which varies from gestational hypertension up to 
severe and early PE. There is also a great variety of biomarkers, and in each study a 
different subset of biomarkers was included.11,19-23 One of the strengths of our cohort is 
the well-defined population of women after early onset PE, all between 20-32 weeks of 
gestation, and the relatively long follow-up period of 10 years post index pregnancy. 
We further composed a set of biomarkers that are involved within various stages of 
endothelial dysfunction and cover the complete spectrum of early atherosclerosis 
development. 
For the analyses of biomarkers in our cohort the Luminex assay was used, which has 
the advantage to enable simultaneously measures up to 100 analytes and uses only very 
small sample volumes.26 However, dilution for different analyses may be different and 
may have influenced the cut-off values for the biomarkers as described in the Methods 
section. 
 
Future perspectives 
Our data indicate that particular CVD biomarkers, SE-selectin and PAPPA, are 
significantly associated with early-onset PE and these associations persist after 
adjustment for traditional CV risk factors (smoking, hypertension and metabolic 
syndrome). These markers express the presence of endothelial dysfunction in women 
post PE and might contribute to their increased cardiovascular risk. Especially PAPPA, 
which is also associated with worse pregnancy outcome and risk on PE,30 could be of 
interest in elucidating the underlying mechanisms between PE and CVD. On the other 
hand, we did find significantly lower levels of ApoB. Future research should focus on 
the role of these novel biomarkers in the pathophysiological process of CVD in women 
post PE. 
The recent 2012 European guidelines on CVD prevention do recommend the use of 
biomarkers in cardiovascular risk prediction in intermediate risk individuals.35 More 
research on the prognostic impact and utility of these biomarkers in general 
cardiovascular screening programmes, but especially in subgroups of high-risk 
individuals such as women with a history of PE, is needed. 
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CONCLUSION 
 
In this cross-sectional cohort analysis we demonstrated an independent association of 
SE-selectin and PAPPA (markers of vascular dysfunction) with PE, which may 
contribute to future cardiovascular events in women post PE. However, ApoB a lipid-
marker was significantly lower and could be protective in these women. Our results 
show that despite correction for traditional cardiovascular risk factors vascular 
dysfunction, as measured by biomarkers, is ongoing in women post PE. The 
mechanisms by which these biomarkers are involved in the increased cardiovascular 
risk warrant further investigation. 
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ABSTRACT  
 
Objective: Women with a history of preeclampsia (PE) are at increased risk for future 
hypertension and cardiovascular disease (CVD). Until now it is not clear whether 
preventive measures are needed in these high-risk women. In the present study we 
evaluated the cost-effectiveness of a simple hypertension screening strategy in women 
post PE. 
Design and setting: A decision-analytic Markov model was constructed to evaluate 
health care costs and effects of screening for hypertension post PE based on available 
literature.  
Participants: Women with a history of preeclampsia with and without (treated) 
hypertension. 
Intervention: Screening consisted of a postpartum annual blood pressure measurement 
during a timeframe of 20 years.  
Main outcomes: Cardiovascular events and CVD mortality were defined as health 
states. Outcomes were measured in absolute costs, events, life-years and quality-
adjusted life-years (QALYs). Sensitivity and threshold analyses were performed to 
address uncertainty. 
Results: Over a 20 year time horizon events occurred in 0.072% of the population after 
screening, and in 0.085% of the population without screening. QALYs increased from 
16.38 (no screening strategy) to 16.41 (screening strategy), an increment of 0.03 
(95%CI 0.01; 0.05) QALYs (12 days in perfect health). Total expected costs were 
€7,834 in the screening strategy, and €9,038 in the no screening strategy, an expected 
saving of €1,203 (95%CI -3223; -247) per person. 
Threshold analysis demonstrated that screening remained cost saving up to annual 
screening costs of €166 per year.  
Conclusion: Annual hypertension screening in women with a history of PE may save 
costs, for at least similar quality of life and survival due to prevented CVD compared 
with standard care. 
 
 
INTRODUCTION 
 
It has been well established that women with a history of preeclampsia (PE) are at 
increased risk of future cardiovascular disease (CVD) morbidity and mortality.1 
Preeclampsia is defined as de novo hypertension (>140/90 mmHg) with proteinuria 
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(>0.3 g/24 h) occurring in the second half of pregnancy.2 It complicates about 2-8%3 of 
all pregnancies, which emphasizes the magnitude of the problem. Despite the abundant 
evidence on the increased CVD risk in these women later in life,4-6 intermediate 
follow-up data are still relatively scarce and it is undefined yet whether preventive 
measures are needed.7   
In the Preeclampsia Risk EValuation in FEMales (PREVFEM) cohort, consisting of 
339 women with a history of early PE (before 32 weeks of pregnancy), we previously 
identified hypertension as the most important CVD risk factor at a cardiovascular 
screening 10 years post-partum. At this screening, participating women were on 
average 40 years of age.8 As hypertension is an established CVD risk factor9, early 
detection and treatment of hypertension seems to be important for this category of 
young women. Obstetric guidelines on treatment of hypertensive disease of pregnancy 
(HPD) recommend that women with a history of HPD should pursue a healthy lifestyle 
and might benefit from assessment of CVD risk factors.10 However, screening onwards 
from pregnancy is labour-intensive and may be costly. It is unknown whether these 
costs are outweighed by the potential improvements in quality of life and long-term 
prognosis, as the CVD event-rate in young women is low. Currently, no data on cost-
effectiveness of preventive interventions in women after PE are available. We 
performed a model-based cost-effectiveness analysis to estimate the health care costs 
and potential effects of screening for hypertension in women with a history of (early) 
PE.  
 
 
METHODS  
 
Overview 
A decision-analytic Markov model was constructed to evaluate costs and effects of 
screening for hypertension from a health care perspective in women post PE. In each 
cycle of the model patients were transferred to a certain health state according to the 
calculated transition probabilities as described in the section transition probabilities. As 
health states (Figure 1) we defined hypertension (treated and untreated) and the most 
common CVD events, namely ischemic heart disease, stroke, heart failure and end-
stage renal failure (ESRD). Final states were defined as CVD mortality and mortality 
of other causes. 
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The cycle length was 1 year. We used time horizons of 10 and 20 years because of the 
time needed to develop cardiovascular events in young women. Our starting point was 
at 30 years of age.  
We choose to limit the time horizon to 20 years as we are especially interested in 
potential health gain of prevention in young women starting directly postpartum. 
During these 20 years before menopause women normally have limited healthcare 
contacts without routinely cardiovascular risk assessment, while after menopausal 
transition CVD prevention is already recommended in current guidelines.11 
Outcomes were measured in number of events, life-years, quality-adjusted life-years 
(QALYs) and absolute costs. The Markov model was built and analyzed in Microsoft 
Office Excel 2010. 
 
 
Figure 1: Schematic representation of the Markov model. *The ‘cardiovascular event’ health 
state is subdivided into ‘ischemic heart disease’, ‘stroke’, ‘heart failure’ and ‘renal failure’. 
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MODEL CONSTRUCTION 
 
Patient characteristics 
As target population we used the PREVFEM cohort, comprising women with a history 
of early-onset PE, defined as an elevated diastolic blood pressure >90 mmHg with 
proteinuria (>0.3 g/ 24 h) developing between 20 and 32 weeks of gestation.12 In this 
study we evaluated the presence of CVD risk factors in women at 10 years after index 
pregnancy compared to a reference cohort of age-matched women with uncomplicated 
pregnancy. We consecutively invited all women registered with early-onset PE at the 
hospital department of obstetrics during the time-period 1991-2007 to participate in 
this cohort study (n=528). Approval for the study was obtained from the institutional 
review board of the Isala klinieken in Zwolle. The detailed protocol of the screening 
procedure has been described elsewhere, as well as the used definitions of CVD risk 
factors.8 
 
Comparators 
We introduced a hypothetical annual blood pressure screening at the general 
practitioner (GP) for women after PE starting in the first year postpartum. The 
comparative strategy existed of care as usual: standard obstetric care and no specific 
arranged blood pressure check-ups. If hypertension (repeated measurements with a 
systolic blood pressure (SBP) >140 mmHg and/or diastolic blood pressure >90 mmHg) 
was detected, in any of the strategies, this involved three additional GP visits, an ECG 
recording and prescription of medication. In the two comparative strategies the 
probability of developing CVD was equal. The only difference between the strategies 
was in detecting and therefore treating hypertension.  
 
Transition probabilities  
Risk of hypertension and presence of adequate treatment for women after PE was 
based on the PREVFEM cohort.8 We made the assumption that women in the 
screening group with established hypertension will be recognized at the screening and 
treated adequately. For women in the non-intervention group we based the probability 
of detected hypertension and adequately treated hypertension on the PREVFEM data.8 
As the follow-up in this cohort is relatively short (10 years) we used published 
literature to assess the risk of future CVD in women post PE (early as well as late PE) 
(Table 1).4,13,14  
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Table 1: Risk of cardiovascular health outcome in women with a history of preeclampsia 
Health outcome Risk (%) /  
(events / total n) 
Follow-up 
(years) 
Ref.  
Hypertension (screening-strategy) 43.1 (146/339) 10    8 
Hypertension (non-intervention strategy)     8 
    On medication 20.6 (70/339) 10   
    Adequately treated   8.0 (27/339) 10   
Ischemic heart disease   1.8 (458/25,148) 14.6  14 
Stroke   1.6 (412/25,184) 14.6  14 
Heart failure   0.5 (123/25,184) 14.6  14 
End-stage renal disease   0.8 (2/242) 40  13 
Cardiovascular mortality   1.0 (167/26,168) 10-42    4 
 
 
Table 2: Relative risk of cardiovascular outcome in participants with untreated hypertension 
Health outcome Relative risk  
(95% confidence interval) 
Distribution Ref. 
Ischemic heart disease 1.32 Fixed 15 
Stroke 1.49 Fixed 15 
Heart failure 1.47 (1.35-1.61) Normal 16 
End-stage renal disease 2.57 (2.06-3.22) Normal 17 
Cardiovascular mortality 1.61 (1.35-1.92) Normal 16 
 
 
 
 
Probabilities of developing CVD for each cycle (Table 2) were derived from meta-
analyses on cardiovascular disease. We assumed that women with a history of PE and 
well treated hypertension (intervention group) are at comparable risk of CVD as 
published in the various cohort studies post PE.4,13,14 Risk reduction in the development 
of ischemic heart disease and stroke were based on the effects of blood pressure 
lowering, starting with a pretreatment SBP of 140 mmHg (as described in the 
hypertensive women of the PREVFEM cohort) and one drug standard dose.15 As Law 
et al did not described the effects of blood pressure lowering on heart failure and 
mortality we used hazard ratio’s (per 20 mmHg SBP increasement) on CVD mortality 
and total CVD events in a Dutch cohort study (35-65 years of age) to estimate the 
effects on these health states.16 The use of a 20 mmHg SBP increasement was based on 
the difference of SBP in women post PE with and without hypertension in the 
PREVFEM cohort.8 Estimation of the relative risk for the development of ESRD was 
also based on a SBP difference of 20 mmHg in a American cohort of 37 years of age.17  
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Table 3: Health care costs 
Health outcome  Event -related  
costs  
(€) 
Long -term treatment, 
 cost / year  
(€) 
Distribution Ref. 
Hypertension 
    Screening/year 
    Treatment  
 
  29.73 
129.52 
 
- 
34.89  
 
Fixed 
Fixed 
 
 
19, 20 
Ischemic heart disease 16,570   1,007 Fixed 18 
(Major) Stroke 34,585 20,194 Fixed 18 
Heart failure   3,707   1,550 Fixed 21, 22 
End-stage renal disease  - 53,961 Fixed 22 
Cardiovascular mortality   4,000 - Fixed 21 
 
 
 
 
Costs  
Costs (Table 3) were presented in the European currency ‘Euro’ (€). Price indices were 
used to convert costs to the 2012 price level. Estimation of costs in the intervention 
strategy was based on a single screening visit at the GP of €30 (Dutch reference price, 
as established by the Dutch Health Care Insurance Board).18 Costs for detection of 
hypertension in both strategies were based on three GP visits and an ECG recording 
(€130) and yearly costs for treatment of hypertension and medication use according to 
current Dutch GP guidelines.19,20 Costs associated with the potential health outcomes 
and yearly ongoing cost thereafter were derived from published Dutch cost studies.11,21 
If these data were not available (for event-related costs of heart failure and treatment 
associated with ESRD), we used other European studies.22 As advised in the Dutch 
guideline, future expenditures were discounted to their present value by a rate of 4%.18 
 
Effects 
Quality-adjusted life years (QALYs) were used as outcome measure in the model. 
These are defined as a combination of survival and health-related quality of life. To 
measure health-related quality of life we used a single index utility, on a scale from 0 
(death) to 1 (perfect health). Utility data (Table 4) were derived from recent 
population-based literature.11,23-27 Utility for healthy women and women with (treated 
and untreated) hypertension were equalized, due to the high utility of hypertensive 
patients.11,23 Future effects were discounted to their present value by a rate of 1.5%, 
according to Dutch guidelines.18 
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Table 4: Health outcome associated utility 
Health outcome Utility  (SD) Distribution Ref. 
No hypertension As hypertension   
Hypertension 0.98 (0.005) Beta 23 
Ischemic heart disease 0.837 (0.17) Beta  24 
Stroke 0.70 (0.27) Beta  25 
Heart failure 0.47 (0.32) Beta  26 
End-stage renal disease 0.71 (0.05) Beta  27 
 
 
Analysis 
Total event rates, life years, QALYs and expected costs were calculated for both 
strategies. If one strategy was more effective and less costly, this strategy was deemed 
cost-effective. To see if screening was more costly and more effective, or the opposite, 
incremental cost-effectiveness ratios (ICERs) were calculated by dividing the 
incremental costs by the incremental QALYs. Whether screening is cost-effective 
depends on whether this ICER is below the societal willingness to pay for a QALY. 
The informal willingness to pay in the Netherlands is € 80,000 per QALY for diseases 
with a high burden.18  
 
Sensitivity analysis 
To reflect the uncertainty of the parameter estimates in the model probabilistic sensitivity 
analyses were performed.28 For this purpose distributions were assigned to the model 
parameters. Parameter values were drawn at random from the assigned distributions, 
using Monte Carlo simulation with 1000 iterations. Based on these simulations, mean 
values and 95% confidence intervals surrounding the costs and effects were calculated. 
The results of this probabilistic analysis are demonstrated in a cost-effectiveness plane 
and cost-effectiveness acceptability curve (CEAC). The CEAC shows the probability 
that screening is cost-effective over a range of willingness to pay thresholds.29 
In addition, a threshold analysis was performed to determine the maximum costs of the 
screening strategy. In this threshold analysis the maximum costs of screening are 
determined to establish which screening is the most effective and least expensive 
strategy.  
One-way deterministic sensitivity analyses were performed to evaluate changes in 
quality of life of women with hypertension. First, we decreased the utility score of 
treated and untreated hypertension to 0.95 and 0.90. Second, we analyzed two different 
scenarios with a lower utility of untreated hypertension compared to treated 
hypertension. 
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Table 5: Cost-effectiveness results, based on the probabilistic analysis 
 Screening strategy 
Mean (95% CI) 
No screening strategy 
Mean (95% CI) 
Increment 
Mean (95% CI) 
Expected health care costs (€)    
   10 year horizon 2,987  3,062  -75  
 (1,826; 5,434) (1,738; 5,751) (-424; 91) 
   20 year horizon 7,834  9,0.38   -1,203  
 (4,492; 14,793) (4,764; 17,703) (-3,223; -247) 
    
Expected life years    
   10 year horizon 9.1715  9.1700  0.0015  
 (9.1674; 9.1750) (9.1657; 9.1739) (0.0008 0.0023) 
   20 year horizon 16.9525  16.9423  0.0102  
 (16.9397; 16.9652) (16.9267; 16.9574) (0.0049; 0.0157) 
    
Expected QALYs    
   10 year horizon 8.93  8.92  0.0046  
 (8.82; 9.02) (8.81; 9.02) (0.0021;0.0077) 
   20 year horizon 16.41 16.38 0.0315  
 (16.17; 16.65) (16.13; 16.63) (0.0140; 0.0537) 
 
 
 
RESULTS 
 
Base case analysis 
Screening for hypertension was found to be slightly more effective than no screening 
(Table 5). Over a 10 year time horizon, screening for hypertension results in 0.037% of 
the population having an event (either ischemic heart disease, stroke, heart failure, 
ESRD or CVD mortality), while this is 0.041%  without screening. Screening provides 
an expected efficacy of 9.1715 life years and 8.93 QALYs, whereas for the no-
screening strategy these results were 9.1700 life years and 8.92 QALYs. The increment 
of the screening strategy over 10 years was 0.0015 (95%CI 0.0008; 0.0023) life years 
and 0.005 (95%CI 0.0021; 0.0077) QALYs. With an extended time horizon of 20 years 
these differences became larger. Events occurred in 0.072% of the population after 
screening, and in 0.085% of the population without screening. Life years in the 
screening strategy were 16.9525 versus 16.9423 in the no screening strategy, an 
increment of 0.0102 (95%CI 0.0049; 0.0157) life years. QALYs increased to 16.38 for 
the no screening strategy and to 16.41 for the screening strategy, an increment of 
0.0315 (95%CI 0.0140; 0.0537) QALYs, which equals 12 days in perfect health 
quality.  
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Screening was also found to be less expensive than no screening. Estimated 
expenditures over a 10 year time horizon were €2,987 for the screening strategy and 
€3,062 for the no screening strategy, a saving of €75 (95%CI -424; 91) per person in 
ten years. Over a 20 year time horizon total costs in the screening strategy increased to 
€7,834, whereas in the no screening strategy to €9,038. This further increases the 
savings to €1,203 (95%CI -3223; -247) per person.  
 
Sensitivity analysis 
The results of the probabilistic sensitivity analysis showed that despite considerable 
uncertainty, in almost all simulations the screening strategy is less costly and more 
effective than the no screening strategy over 20 years (Figure 2). From the CEAC it is 
clear that regardless of the willingness to pay for a QALY, screening has a probability 
of being cost-effective over 99% (Figure 3). 
 
 
 
Figure 2: Effectiveness of screening for hypertension post preeclampsia according to the 
probabilistic analysis in 20 year time horizon. 
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In the threshold analysis, screening remained the least costly strategy over 20 years up 
to costs of screening of €166 per year. 
Table 6 shows the one-way sensitivity analysis on utility. Lowering the utility of both 
treated and untreated hypertension reduced the QALYs gained in the screening 
strategy. But on the opposite, if we decreased the utility of untreated hypertension, with 
unchanged utility of treated hypertension, the QALY gain of screening increased. By 
using a combination of lower utility of treated hypertension (0.97) compared to a 
healthy state (0.98) and a utility of 0.95 for untreated hypertension, incremental 
QALYs of screening raised to 0.132. For each variation in utility the screening strategy 
remained the most effective strategy. 
 
 
 
 
Figure 3: Cost-effectiveness acceptability curves for hypertension screenig in women post 
preeclampsia, combined results for 10 and 20 year time horizon. 
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Table 6. Results of the deterministic threshold and sensitivity analysis (over 20 years) 
 Incremental 
costs screening 
(€) 
Incremental 
QALYs 
screening 
Incremental costs per 
QALY gained 
Base case analysis -1195 0.03 Screening dominates 
Costs of screening €166 -5 0.03 Screening dominates 
Utility hypertension 0.95 -1195 0.03 Screening dominates 
Utility hypertension 0.90 -1195 0.03 Screening dominates 
Utility untreated hypertension 0.95 -1195 0.18 Screening dominates 
Utility untreated hypertension 0.90 -1195 0.44 Screening dominates 
Utility untreated hypertension 0.90,  
    treated hypertension 0.95 
-1195 0.28 Screening dominates 
Utility untreated hypertension 0.95, 
    treated hypertension 0.97 
-1195 0.13 Screening dominates 
 
 
 
 
 
DISCUSSION 
 
In this model-based analysis we assess the expected cost-effectiveness of a 
hypertension screening strategy in women after PE. We found that a relatively simple 
preventive strategy, consisting of a yearly blood pressure measurement at the GP after 
index pregnancy, is less expensive and more effective than current standard care 
without regular control. Over 20 years, screening for hypertension gives an expected 
saving of €1,203 per person and a slight increment of 0.03 QALY, i.e. an increase of 
12 days living in perfect health per screened person.  
 
Cardiovascular risk and preeclampsia 
Several studies have clearly demonstrated the increased risk for CVD in women with a 
history of PE.1,4,5 Especially women after early and severe PE are at higher risk for 
future CVD.1,14 The 2011 AHA guidelines on cardiovascular disease prevention in 
women do recognize pregnancy as a unique chance to predict women’s lifetime 
cardiovascular risk, as pregnancy-related complications may unmask premature 
vascular of metabolic diseases.7  Therefore appropriate monitoring of CVD risk factors 
in these high risk women is recommended.7 The 2012 ESC guideline on CVD 
prevention also indicates that prevention of CVD in women ideally starts during 
pregnancy and lasts until end of life.9 However, in standard primary care obstetric 
 
Cost-effectiveness of hypertension screening post preeclampsia 
___________________________________________________________________ 
92 
 
history is not yet routinely incorporated.30 The NICE guideline ‘Hypertension in 
pregnancy’ recommend physicians to inform women with a history of HPD about the 
future risk of hypertension and associated complications.31 The Dutch multidisciplinary 
guideline on cardiovascular risk management advises cardiovascular risk assessment in 
postmenopausal women who previously had pregnancy-related hypertensive 
complications.11 However, in our analysis we showed that an important preventive 
effect may already be reached in women before menopause.  
 
Strenghts and limitations 
In our Markov model analysis we demonstrated cost-effectiveness of cardiovascular 
prevention in women with a history of preeclampsia. The power of this model is 
founded in combining the available evidence on CVD post preeclampsia. Our model 
could be of help in making evidence-based decisions on prevention post preeclampsia, 
without performing complex and costly long-term follow-up studies.  
However, our model has some limitations. To estimate risk of hypertension in women 
after PE we used the PREVFEM cohort, a well-defined cohort of women with a history 
of early PE. As this hypertensive pregnancy disorder confers the highest future CVD 
risk1,14, the used risk on future hypertension and therefore the effectiveness of our 
Markov model might be overrated for women with a later occurrence of PE and other 
HPD. However, as prospective data in women after early PE are relatively scarce, we 
also used future CVD risk data of patients with less severe forms of PE to estimate risk 
on future CVD post PE. This may have underestimated the net effect in our model. 
Nonetheless the presented data are convincing and underline the need for preventive 
measures in these high-risk women.  
In our model we used mainly Dutch costs. As costs in other jurisdictions will be 
different from the Dutch situation, our results could be less generalizable to other 
health systems. However, in general costs in the US tend to be higher than in the Dutch 
health care system, so savings in the US will probably turn out to be larger. On the 
other hand, the Dutch well-structured GP system can adopt our intervention strategy 
easily, whereas this might be more difficult in other countries with a less developed GP 
system. Given our detailed presentation of the model and its input parameters, 
interested readers can assess the transferability of the results to their specific 
situation.32 
To perform our model we made some assumptions. First, we assumed that women with 
non-treated hypertension in the non-intervention strategy had a 20 mmHg higher SBP 
than women with adequate treated hypertension in the intervention strategy, based on 
our PREVFEM data. This seems reliable if women in the intervention strategy are 
 
Chapter 7 
___________________________________________________________________ 
93 
 
directly well controlled and treated, but in current daily practice this is still 
disappointing.33,34 In our model partcipants were all compliant in taking 
antihypertensive medication, in realilty a quarter of women on blood pressure 
medication does not take them regularly, which will reduce the calculated preventive 
effects.35   
Second, to estimate the increase in CVD risk in the presence of increased blood 
pressure we used a meta-analysis and two cohort studies, these studies consisted of 
men and women with an age distribution between 35 and 65 years old. Our Markov 
model focuses on women between 30 and 50 years old. Use of data based on both men 
and women might have overrated over effects as men have higher CVD rates at 
younger ages.36   
Finally, we assumed that women with and without hypertension have the same utility 
score and only adapted utility if one of the defined health states was achieved. The 
study of Stein et al. indicates that patients with hypertension do not experience the 
lower quality of life which is expected by healthy individuals and clinicians.23 
However, we can imagine that both treated hypertension (with use of medication and 
lifestyle adaptations) and untreated hypertension (with potential health complaints) 
influence utility. We evaluated potential adaptation of utility in the sensitivity analyses 
and demonstrated that screening remains less costly and more effective in each 
variation (Table 6).  
 
Clinical implications and future perspective 
In our model we demonstrated that a yearly blood pressure measurement at the GP post 
preeclampsia is less expensive and more effective than current standard care without 
regular blood pressure control in prevention of CVD. However, in a time horizon of 20 
years we found only a slight gain in QALYs (15 days living in perfect health per 
screened person). Although this gain is associated with cost savings, the clinical 
relevance of this small gain in QALYS can be discussed. Besides the relevance of this 
health effect we also need to consider the willingness of young, healthy women to use 
blood pressure medication, with potential side effects, for a 15 days longer life in 
perfect health. Further, before considering to incorporate a screening strategy into new 
primary care guidelines, it should be investigated if the used strategy is attainable for 
GPs. Despite the cost-effectiveness of hypertension screening postpartum, it gives a 
potential burden for GPs and women post PE. This may be decreased by starting 
screening at 10 years postpartum or by reducing the frequency of the screening to once 
in 2 years. More research is needed to establish the best time-schedule for hypertension 
screening. For the future, there might be an interesting role for e-health medicine in 
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prevention of CVD in young high-risk women post PE. This also needs to be 
investigated. 
 
 
CONCLUSION 
 
Annual hypertension screening in primary care in women after PE is cost-effective in 
preventing future CVD. 
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ABSTRACT 
 
Objective: Cardiovascular disease is the major cause of mortality in women worldwide.  
In recent years, several female-specific cardiovascular risk factors, such as 
hypertensive pregnancy diseases (HPD) and vasomotor menopausal symptoms (VMS), 
have been identified. In this study, we evaluated the association between a history of 
HPD and the presence of VMS. 
Methods: We consecutively included 853 women (mean age 55.5 years) who visited 
the outpatient cardiovascular clinic for women in Kampen between 2003 and 2010. 
The visit included a questionnaire on history of HPD, demographic characteristics and 
VMS; a physical examination; and blood sampling. Logistic regression analysis was 
used to analyse the data.  
Results: A history of HPD was reported by 274 women (32%) and VMS were reported 
by 83% of women with HPD in history and 75% of women without HPD in history. In 
adjusted models, VMS were more often present (odd ratio [OR] 1.62; (95%CI 1.00; 
2.63), and more frequently persisted for longer than 1 year (OR 2.05; 95%CI 1.08; 
3.89) among women with a history of HPD than among women with normotensive 
pregnancies. VMS were more often severe in women with history of HPD, but this did 
not reach significance (adjusted OR 1.28; 95%CI 0.92; 1.80). The frequency and 
intensity of VMS did not differ between both groups. 
Conclusion: In our ‘Kampen women cardiology clinic’ cohort, women with a history 
of HPD report VMS during the menopausal transition significantly more often than 
women with normotensive pregnancies. 
 
 
INTRODUCTION 
 
Cardiovascular disease is one of the most important causes of death in men and 
women.1 For women, several female-specific risk factors have been identified.2 
Hypertensive pregnancy diseases (HPD), especially early preeclampsia, are important 
female specific risk factors that affect future cardiovascular health.3-5 Other pregnancy-
related complications, such as placental syndrome (abruption or infarction) or 
gestational diabetes mellitus, also contribute to an increased cardiovascular risk.6,7 
Although the underlying mechanisms are not clear yet, endothelial dysfunction and an 
exaggerated systemic inflammation after a complicated pregnancy are likely to play a 
role in the increased cardiovascular disease (CVD) risk.8 The presence of vasomotor 
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menopausal symptoms (VMS), another characteristic of reproductive health and 
commonly referred to as night sweats and hot flushes, is also associated with a less 
favorable cardiovascular risk profile and an increased CVD risk.9,10 VMS reflect 
reduced vascular reactivity, manifested by oxidative stress and endothelial dysfunction, 
and are also associated with increased carotid intima media thickness.11,12 
Despite the fact that HPD and VMS are both associated with an increased 
cardiovascular risk that seems to be mediated through endothelial dysfunction HPD 
and VMS have never been evaluated to be related. Vascular dysfunction in women 
with a history of hypertensive diseases in pregnancy may lead to an increase in VMS as 
a sign of reduced vascular reactivity during menopause transition. More information on 
the association between HPD and VMS may lead to a better understanding of both 
phenomena and result in possible preventive measures.  
In the present study we examined whether a history of HPD is associated with the 
presence, duration, severity, frequency and intensity of VMS  
 
 
METHODS 
 
Population 
The study included consecutively all 1179 women who visited the weekly outpatient 
cardiology clinic for women in Kampen (Zwolle area, The Netherlands) between 2003 
and 2010. Reasons for visiting the clinic consisted of cardiac complaints, 
cardiovascular screening for an increased family risk or second opinion. Women were 
referred by their primary care physician or other specialist, but also presented on their 
own initiative. Women were aged between 40 and 70 years at consultation. Between 
2009 and 2010, all women were sent an additional questionnaire on presence, duration, 
severity and frequency of VMS. Of 1179 women, 931 returned the questionnaire. Of 
those, 853 women provided data on previous pregnancies and presence of HPD and 
were therefore included in the present analysis.  
 
Measurements 
First intake at consultation was performed by a specialty nurse with a detailed 
questionnaire on demographic characteristics, physical complaints, lifestyle risk 
factors, medication use, cardiovascular history and obstetric history.  
Information on socio-economic status (SES) of the neighborhood has been derived 
from the Social Cultural Planning Office, The Netherlands. The Social Cultural 
 
Chapter 8 
___________________________________________________________________ 
103 
 
Planning Office uses average income, unemployment, and education as indicators for 
the social status. Three SES deprivation categories were formed: low, moderate and 
high. Alcohol consumption was categorized as never; 1-3 units (U)/week; 1-3 U/day 
and >3 U/day. Smoking was defined as current smoking, past smoking or non-
smoking. Sedentary lifestyle was defined as low energy expenditure during daily 
activities and sports activities for 20 min/week or less.  
Menopausal status was defined as follows: women were ‘pre- or perimenopausal’ if 
they reported having menses, and ‘postmenopausal’ if they reported not having 
menses. Women with incomplete questionnaire data or who reported current use of oral 
contraceptives or hormones were classified as pre- or perimenopausal if they were 
between 40 and 55 years of age, and postmenopausal if they were older than 55 years 
of age. Hormone use was defined as ever use of oral anti-conceptive medication, 
hormone therapy, or both. A history of HPD, defined as high blood pressure in one of 
the previous pregnancies or gestational diabetes was based on self-reported history. 
 
Cardiovascular risk parameters 
Physical examination was performed. Weight (kg) and height (m) were measured and 
body mass index (BMI) was calculated as weight in kilograms divided by height per 
meters squared. Waist circumference (cm) was measured with a tape measure at a level 
midway the lowest rib and the iliac crest. All women were measured in underwear and 
barefoot. Furthermore, measurements of blood pressure on both arms and of resting 
heart rate were taken at rest in sitting position. Hypertension was defined as a systolic 
blood pressure of 140 mmHg or higher and/or a diastolic blood pressure of 90 mmHg 
or higher and/or use of antihypertensive medication. Baseline electrocardiogram was 
recorded. A fasting blood sample was taken to analyse glucose, total cholesterol, high-
density lipoprotein cholesterol, cholesterol/high-density lipoprotein cholesterol ratio, 
low-density lipoprotein cholesterol and triglycerides levels (analysed by Roche 
Modular P800). Presence of diabetes mellitus was defined as self-reported treatment 
for diabetes mellitus or a fasting glucose higher than 6.9 mmol/l. Hypercholesterolemia 
was defined as self-reported use of lipid-lowering medication or a fasting total 
cholesterol higher than 5 mmol/l. CVD was defined as a composite endpoint of history 
of myocardial infarction, percutaneous coronary intervention (PCI), coronary artery 
bypass graft or cerebrovascular accident. Family history of CVD was based on self-
report of premature CVD (CVD or multiple cardiovascular risk factors before age of 60 
years in first-degree family members) in the questionnaire.  
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Vasomotor menopausal symptoms 
Presence of VMS was assessed via the additional questionnaire using the following 
question: “Do you currently have or have you had hot flushes and/or night sweats?”- 
with the choices being (a) none; (b) only hot flushes; (c) only night sweats; (d) both hot 
flushes and night sweats. Women were also asked to report the duration of VMS, 
response options ranged from less than 6 months to more than 20 years. Based on this 
answer, duration of symptoms was divided into two classes: symptoms for 1 year or 
less, and symptoms for longer than 1 year.  
Frequency of hot flushes was based on the number of symptomatic days per week 
(range 1-7), multiplied with the number of hot flushes per day (range 1-10 or more). 
The resulting hot flushes frequency score ranged from 1 to 70 and was categorized as 
low (<21); moderate (22-36) or high (>37). Women with missing data on both number 
of symptomatic days and number of hot flushes per day were classified as not having 
had hot flushes. To determine the frequency of night sweats, we combined the data on 
number of symptomatic nights per week (range 1-7) and number of nights sweats per 
night (range 1-14). Based on the resulting night sweats frequency score (range 1-98) 
we created 3 frequency categories: low (<8); moderate (9-15); high (>16) night sweats 
per week. Women with missing data were again classified as not having had night 
sweats. The frequency category of hot flushes was multiplied with the frequency 
category of night sweats, resulting in a total frequency score for VMS (range 1-9). 
VMS frequency categories were formed: low (score of 1-2), moderate (score of 3-4) or 
high (score of >5). Severity of hot flushes and nights sweats was indicated by the 
participants and divided into four categories: (0) no symptoms, (1) symptoms not 
disturbing day/night activities, (2) symptoms disturbing activities day/night, and (3) 
severe symptoms interrupting with activities. We defined symptoms as severe if the 
criteria fulfilled the last two categories. Women with either severe hot flushes, severe 
night sweats or both where defined as having severe VMS or as having had severe 
VMS. 
Finally, we determined the intensity of VMS based on a combination of frequencies of 
VMS, as described before; severity of VMS was determined as indicated by the 
participants. For hot flushes, we multiplied the frequency category (1-3) with the 
severity of symptoms (0-4). Based on this score, we divided the intensity into three 
categories: low (score of 1-2); moderate (score of 3-4); high (score of >5). For night 
sweats, we did the same (frequency category x severity) to determine intensity and 
divide them into three categories. We combined intensity data of hot flushes and nights 
sweats in a new parameter, ‘intensity VMS’: low intense VMS (score of 1-2); moderate 
intense VMS (score of 3-4), and high intense VMS (score of >5).  
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Table 1: Baseline characteristics of the study population (n = 853) by presence of hypertensive 
               pregnancy disease  
Variables With hypertensive 
pregnancy disease 
n = 274 
Mean (SD) or n (%) 
Without  hypertensive 
pregnancy disease 
n = 579 
Mean (SD) or n (%) 
Age visit outpatient clinic (years) 56.5 (7.3)   54.5 (9.3)* 
Cardiac complaints as reason visit clinic 147 (53.4%) 293 (50.6%) 
Current smoking 23 (8.4%) 52 (9.0%) 
Ex-smoking 130 (47.4%) 295 (50.9%) 
Familial history cardiovascular disease 248 (90.5%) 511 (88.3%) 
Alcohol use: 
   never 
   1-3 units/ week 
   1-3 units/day 
    >3 units/day 
 
109 (38.9%) 
  94 (34.3%) 
  65 (23.7%) 
  2 (0.7 %) 
 
210 (36.3%) 
167 (28.8%) 
185 (32.0%) 
 7 (1.2%) 
Sedentary lifestyle  98 (35.8%) 230 (39.7%) 
Socio-economic status (SES) 
   low 
   moderate 
   high 
 
  53 (19.3%) 
150 (54.7%) 
  71 (25.9%) 
 
113 (19.5%) 
329 (56.8%) 
134 (23.1%) 
   
Systolic blood pressure (mmHg) 148.3 (22.4)   142.6 (22.6) * 
Diastolic blood pressure (mmHg)    88.9 (10.7)     85.9 (10.2) * 
BMI (kg/m2) 26.6 (4.6)   25.7 (4.3) * 
Waist circumference (cm)             87 (12)           85 (12) * 
Total cholesterol (mmol/l)   5.6 (1.1)  5.6 (1.1) 
HDL cholesterol (mmol/l)   1.7 (0.5)  1.7 (0.5) 
LDL cholesterol (mmol/l)   3.3 (1.0)  3.3 (1.0) 
Ratio HDL/Total cholesterol   3.6 (1.2)  3.6 (1.2) 
Triglycerides (mmol/l)   1.5 (1.0)  1.4 (1.1) 
Glucose (mmol/l)   5.5 (1.2)     5.3 (0.8) * 
   
Hypertension  211 (77.0%)    341 (58.9%) * 
Use anti-hypertensiva   86 (31.4%) 128 (22.1%) 
Hypercholesterolemia  93 (33.9%) 193 (33.3%) 
Statin use             27 (9.9%)   62 (10.7%) 
Diabetes mellitus             15 (5.5%) 27 (4.7%) 
Cardiovascular disease             15 (5.5%) 28 (4.8%) 
   
Parity (n) 2.6 (1.1)   1.9 (1.3) 
Miscarriages and stillbirths  88 (32.1%) 163 (28.2%) 
Gestational diabetes mellitus            15 (5.5%)    13 (2.2%) * 
Pre-/perimenopausal  46 (16.8%)   170 (29.3%) * 
Use of oral contraceptives or  
  hormone therapy in history  
         236 (86.1%)   466 (80.4%) * 
*p<0.05. 
 
 
 
Association between HPD and VMS 
___________________________________________________________________ 
106 
 
Data analysis 
Baseline characteristics were described as mean (SD) for continuous data and as 
frequency (%) for categorical data. Differences between women with HPD and women 
without HPD were analyzed with independent-sample Student’s t-test for continuous 
data and with X2 or Fisher exact test for categorical data, when appropriate. 
Logistic regression analysis was used to analyse the associations between the presence 
of HPD and the risk of VMS. We present odds ratios (OR) with 95% confidence 
intervals (CI) as crude OR and after stepwise adjustment according to three models. 
Model 1 only adjusts for age; model 2 for age, SES, sedentary lifestyle, smoking, 
hormone use (ever) and menopausal status; and model 3 for age, SES, sedentary 
lifestyle, smoking, hormone use (ever), menopausal status, BMI and hypertension.  
Data analyses were performed with SPSS software (version 16.0). All p values were 
two-sided; statistical significance was assumed when two-tailed probability value was 
less than 0.05. 
 
 
 
 
 Table 2: VMS by presence of hypertensive pregnancy disease (n = 853) 
Variable With hypertensive pregnancy 
disease 
n = 274 
n (%) 
Without hypertensive 
pregnancy disease 
n = 579 
n (%) 
VMS  226 (82.5%)    433 (74.8%) * 
Only night sweats  
Only flushes  
Both  
  35 (12.8%) 
19 (6.9%) 
165 (60.2%) 
  73 (12.6%) 
39 (6.7%) 
314 (54.2%) 
Age at first VMS (year) 48.2 (5.0) 47.8 (5.3) 
Duration VMS >1 year  196 (71.5%)    346 (59.8%) * 
Severe VMS 166 (60.6%)    307 (53.0%) * 
Frequency VMS 
   low 
   moderate 
   high 
 
120 (43.8%) 
  41 (15.0%) 
  53 (19.3%) 
 
265 (45.8%) 
    59 (10.2%) * 
 85 (14.7%) 
Intensity VMS 
   low 
   moderate 
   high 
 
116 (42.3%) 
  34 (12.4%) 
  63 (23.0%) 
 
245 (42.3%) 
 64 (11.1%) 
    99 (17.1%) * 
*p<0.05. VMS, vasomotor menopausal symptoms. 
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RESULTS 
 
The mean (SD) age of 853 women was 55.5 (7.9) years. In total, 274 women (32.1%) 
had a history of HPD. Compared with women who had no history of HPD, those who 
had a history of HPD had a higher BMI, waist circumference, glucose level and blood 
pressure, and were more likely to have a history of gestational diabetes, to be 
postmenopausal and to have hypertension (Table 1).  
Women with previous HPD significantly more often had VMS (82.5%) during the 
menopausal transition than women without HPD (74.8%), as demonstrated in Table 2. 
Most symptomatic women reported both night sweats and hot flushes (73% in both 
groups). Age at first symptoms was equal between both groups, with a mean age of 48 
years. Other VMS parameters are described in Table 2. Table 3 shows the associations 
between HPD and VMS characteristics. The crude OR (95%CI) for the presence of 
VMS in women with a history of HPD was 1.73 (1.15; 2.59) compared with women 
without history of HPD. After stepwise correction for potential confounders in 
different models, as described above, the presence of VMS was still significantly 
higher in women with history of HPD compared with women with normotensive 
pregnancies  (OR 1.62, 95%CI 1.00; 2.63). Women with previous HPD more often had 
symptoms with a duration longer than 1 year compared with women without HPD (OR 
2.05, 95%CI 1.08; 3.89). In addition, their symptoms were more often severe, with a 
crude OR (95%CI) of 1.36 (1.02; 1.82).  After correction for potential confounders, 
however, this association attenuated to non-significance, with an OR (95%CI) of 1.28 
(0.92; 1.80). The frequency and intensity of VMS did not differ for women with and 
without a history of HPD. 
 
 
DISCUSSION 
 
In this study, we found that VMS during menopause occur more often in middle-aged 
women with a history of hypertensive disease in pregnancy (at our ‘Kampen women 
cardiology clinic’) than in women with a history of normotensive pregnancies. VMS in 
women with a history of HPD were also more severe and more frequently more 
frequently lasted longer than 1 year compared with women with a history of normo-
tensive pregnancies. However, the magnitude of the association between HPD and 
VMS is modest.  
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This is the first study to investigate the presence of VMS in women with a history of 
HPD. We found an interesting clustering of these female-specific cardiovascular risk 
factors. The development of both HPD and VMS is associated with a number of 
common risk factors, especially higher BMI and abdominal adiposity.8,12-15 However, 
correction for one of the most important confounders (BMI) did not materially change 
the established  association between HPD and VMS, suggesting that other underlying 
mechanisms may be involved.  
Persistent endothelial dysfunction after hypertensive disease in pregnancy, mainly 
described in women post preeclampsia,16,17 may contribute to the development of VMS 
later in life.11 Another possible mechanism is increased sympathic nervous system 
(SNS) activity, which has been suggested to be present in women with VMS. Early 
VMS, occurring at the onset of menopause but not thereafter,10 are presumably 
associated with the change in estrogen levels around menopause. Hormonal changes 
are involved in the activation of the sympathetic nervous system, which triggers a 
lowering of the thermoneutral zone in the brain. Within this re-setting of the 
thermoneutral zone, small increases in core body temperature may induce sweating and 
shivering as core body temperature decreases.18,19 The relation between hypertension 
and increased sympathetic nervous activity and increased plasma catecholamines has 
also been generally acknowledged.20 It is hypothesized that women with a history of 
HPD – especially if they remain hypertensive after pregnancy – experience increased 
SNS activity, which may explain the association between HPD and VMS, as described 
by Collén et al.21 More data on SNS activity in women with history of HPD are needed 
to examine this hypothesis. 
Strengths of our study include the number of women and the high response rate (79%) 
on the VMS questionnaire. The questionnaire on VMS was extensive and included 
duration, severity, frequency and intensity of VMS. The design of our study, which 
included women with different reasons for referral, may have induced inclusion bias, 
however. Half of the women who visited the outpatient cardiovascular women clinic in 
Kampen were referred to the cardiologist because they had cardiac symptoms 
(comparable in women with and without history of HPD). This means that our data 
cannot be generalized to all middle-aged women. Furthermore, one in three women had 
a history of HPD, which is not representative of the general female Dutch population 
(10% prevalence of HPD, including gestational hypertension and preeclampsia).22 
Moreover, 30% of the women in this cohort reported a history of miscarriages and 
stillbirths, which is higher than the 15-20% expected. We speculate that, through self-
selection, we have a population at increased cardiovascular risk. That pregnancy loss is 
associated with a doubling of the cardiovascular risk23, may explain the enrichment of 
 
Association between HPD and VMS 
___________________________________________________________________ 
110 
 
women with pregnancy losses in this study population. When we additionally adjusted 
the relation between HPD and VMS for the presence of a history of miscarriage and 
stillbirth, the association did was not attenuated (OR 1.72 95%CI 1.04; 2.82). 
Another limitation is the self-reported history of both HPD and VMS. The specificity 
of self-reported HPD is rather high (95-100%), however, sensitivity is lower (ranging 
from 23% to 85% for different HPD).24,25 As self-report of HPD is probably not related 
to reporting of VMS, we assume that the recall bias of HPD most probably have led to 
an underestimation of the association between HPD and VMS. Furthermore, we do not 
have any data available on the severity of the reported HPD, birth weight, and 
gestational age at delivery. This information is important for future research because 
these parameters influence long-term health outcomes in affected women.6 The use of 
self-reported VMS data may have induced recall-bias and fails to discriminate between 
the occurrence of early VMS and the occurrence of late VMS, which may also affect 
future cardiovascular risk.10 Finally, menopausal status was categorized according to 
bleeding patterns and is therefore likely to reflect women’s experiences.  This differs 
slightly from the recent proposed Stages of Reproductive Aging Workshop definition 
that also takes hormone levels into account.26 
We recommend additional observational research in the general female population to 
test the consistency and magnitude of our found associations in a more general female 
population and to reveal more of the underlying pathophysiological mechanisms 
between HPD and VMS. The next step would be to investigate the cardiovascular risk 
in women with both history of HPD and history of VMS later in life, as both HPD and 
VMS have been founded to increase CVD risk. Preventive measures among women 
with history of HPD are currently under debate, but expert opinion tends to advise 
monitoring of cardiovascular risk factors in women after HPD.2,26 
 
 
CONCLUSION 
 
In our ‘Kampen women cardiology clinic’ cohort, women with a history of HPD report 
significantly more VMS compared to women without a history of HPD. As the 
adjusted differences between both groups are only borderline significant, more research 
is needed to evaluate these associations in a general female population.  
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Cardiovascular disease (CVD) is the leading cause of death in Europe, with a 
percentage of 46% of all deaths, and causes a substantial burden to health care 
systems.1 Mortality from CVD in women is even higher than in men, 51% versus 
42%.1 Traditional CVD  risk factors for both sexes are well defined, but emerging data 
in the last decades have shown that   female-specific factors, related to hormonal and 
reproductive status  are importantly involved in the development of atherosclerosis in 
women.2 Pregnancy is increasingly considered as a maternal “stress test” for future 
CVD risk. Certain disorders of pregnancy, such as hypertension and diabetes,  can 
unmask a woman’s vulnerability for CVD (Figure 1).3,4  
Of the various  hypertensive pregnancy diseases (HPD), preeclampsia (PE) seems to 
have the most detrimental effects on future cardiovascular health.5,6 In the present 
thesis we focused on the development of CVD risk factors at intermediate term in 
women post HPD, and mainly PE, to identify possible targets for timely  intervention.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Pregnancy as stress test for future health, from Powe 2011.4 
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CARDIOVASCULAR RISK FACTORS POST PE 
 
The higher risk of CVD later in life in women post PE has been found in several large 
studies and meta-analyses.5,7,8 With a mean follow-up of 15 years postpartum Bellamy 
et al. ascertained a relative risk (RR) of 3.7 for hypertension; 2.2 for ischemic heart 
disease; and 1.5 for overall mortality.5 Over 30 years of follow-up Wilson et al. found 
an odds ratio (OR) of 4.0 for hypertension and 3.4 for stroke in women after PE.9 
However, before CVD events occur the first signs of impaired cardiac function are 
already apparent.10 Prevention should therefore start many years earlier. Before we can 
establish the ideal timing for preventive measures, we first need to understand the 
development of CVD risk in women post PE. For this purpose we performed the 
PREVFEM study (Preeclampsia Risk EValuation in FEMales) and determined the 
prevalence of traditional CVD risk factors in women at 10 years post PE, and 
compared these in women with uncomplicated pregnancies. In this study we 
demonstrated that at 10 years post index pregnancy hypertension and the metabolic 
syndrome (MetS), predominantly based on high blood pressure and waist 
circumference,  are significantly more prevalent in women post PE compared to the 
reference group (CHAPTER 4). Prevalences of hypercholesterolemia and diabetes 
mellitus were not different. We conclude that women post PE already are more often 
hypertensive within 10 years post index pregnancy, which imposes an increased CVD 
risk on the longer term. Despite the increased prevalence of hypertension, we did not 
find any differences between women with and without history of PE in hypertension 
associated electrocardiographic deviations (CHAPTER 5). Probably it takes longer than 
10 years post PE to develop identifiable hypertension induced ECG changes. However, 
we do know that the sensitivity of ECG criteria for left ventricular hypertrophy (LVH) 
is low in detecting the detrimental effects of hypertension. Although its specificity is 
high, echocardiography has a higher sensitivity of demonstrating diastolic dysfunction 
and LVH.11 Echocardiography in women at 9 months post PE demonstrates an 
increased left ventricular mass preceding chronic hypertension.12 
For women with milder forms of hypertensive pregnancy disorders (HPD) in the 
Doetinchem cohort, we also found increased levels of blood pressure (systolic and 
diastolic) and BMI during follow-up. Another apparent finding in our analysis in the 
Doetinchem Cohort was the comparable annual changes of various CVD risk factors in 
women with and without previous HPD. The established baseline differences in blood 
pressure and BMI between both groups does not further diverge with age (CHAPTER 3). 
Based on these data we hypothesize that HPD initiates a change in the metabolic 
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constitution of affected women postpartum, which does not deteriorate with age. 
Literature shows that pre-pregnancy CVD risk factors importantly (in 50-65%) 
contribute to the postpartum elevated risk after  HPD.13 This  may  indicate a life-time 
different metabolic constitution for women who develop HPD.  
In both our cohorts we found no differences in lipid levels between women with and 
without HPD complications. The literature on lipid levels in women post HPD is not 
consistent. Some studies found unfavorable lipid profiles after HPD shortly 
postpartum14, but also on the long term until 16 years postpartum.13,15 However, the 
reported  differences long after HPD were demonstrated in large cohort studies, but 
were very small (approximately 4%) and maybe even not clinical relevant.13,15 Others 
described comparable  lipid levels in women with and without HPD.16,17 Participating 
females within both the PREVFEM  and the Doetinchem cohort study were still mainly 
premenopausal and their estrogen status may override the harmful effect of PE on lipid 
levels.18,19 It may  be relevant  to evaluate lipid levels consecutively over time and to 
determine whether disturbed lipids shortly postpartum persist over time. It is unknown 
yet whether menopause-related lipid changes are more adverse in women after HPD 
than in women after normotensive pregnancies. 
 
 
PROGRESSION OF VASCULAR AGEING POST HYPERTENSIVE  
PREGNANCY DISORDERS 
 
Given the increased CVD risk in young women post PE, it is still uncertain which 
mechanisms are involved in this increased risk. To better understand these causative 
factors we first need to understand the pathophysiologic mechanisms leading to a 
preeclamptic pregnancy. The currently most accepted hypothesis is that the primary 
cause of PE is a disturbed placental function, provoked by impaired throphoblast 
invasion and poor spiral artery invasion throughout the placenta, developing between 
week 8-18 of gestation.4,20 As a consequence of this disturbed placental function, 
oxidative stress arises with the release of several anti-angiogenic proteins and 
cytokines. These have a synergistic role and lead to an exaggerated endothelial 
activation with a generalized maternal systemic inflammatory response.20-22 This 
results in the clinical features of PE, hypertension and proteinuria, which may arise 
from the 20th week of gestation.4,20,21  
The extent of this maternal systemic response is dependent on several maternal 
constitutional factors like genetics and environmental factors.23 Pre-existing medical 
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conditions such as hypertension and DM, but also renal diseases and the 
antiphospholipid syndrome are risk factors for development of PE.24 Genetics are also 
importantly involved in the pathophysiology of PE.23 This is demonstrated by the 
increased risk of developing PE in  women with a positive family history of CVD and 
by the increased risk of PE after a partner change (paternal antigen exposure).23,24  Until 
now single gene studies have not given clear answers,23 while a recent meta-analysis 
identified two prothrombotic gene variants but with moderate epidemiological 
reliability because of moderate amount of evidence for one, and inability to rule out 
protection from bias for both.25 Most studies on genetics in PE are relatively small and 
focus on candidate genes, while PE is a complex disease. In the ongoing Genome Wide 
Association Studies (GWAS) more information will be ascertained on the role of 
genetic determinants and environmental exposure in the development of PE.25  
It is assumed that persistent endothelial dysfunction post PE is an important factor for 
the increased future CVD risk later in life.26 However, studies on cardiovascular 
biomarkers in these women are very heterogeneous and inconsistent.17,27-30 Insulin 
resistance post PE has been recurrently described as the possible link between PE and 
future CVD.29-31 Pre-pregnancy insulin resistance has been shown to be a risk factor for 
the development of PE and is also related with chronic hypertension and a higher 
BMI.32 This supports a variety of  metabolic constitutions in  women at risk. In 
CHAPTER 6 we described levels of biomarkers associated with different stages of CVD 
development in women post PE. SE-selectin and pregnancy-associated plasma protein 
A (PAPPA) were significantly increased in women post early-onset PE, independent of 
traditional CVD risk factors. Especially the increased level of PAPPA is interesting, as 
this factor is associated with vulnerable atherosclerotic plaques.33 This may lead to the 
hypothesis that women post PE may develop plaques that are involved in premature 
atherosclerotic disease. The potentially higher vulnerability of these plaques may 
contribute to earlier manifestation of CVD events.  
Besides the differences in levels of biochemical markers, which may reflect endothelial 
dysfunction, impaired endothelial function can be measured. Two studies have  
demonstrated impaired endothelial function in women post PE compared to women 
after uncomplicated pregnancies in the early postpartum period (respectively after 3 
and 16 months).27,34 However, intermediate and long term follow-up data on vascular 
endothelial function are very scarce. This information is needed to test the hypothesis 
that persistent endothelial dysfunction postpartum is responsible for the increased CVD 
risk later in life.  
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EARLY AND LATE PE 
 
Preeclampsia, defined as hypertension and proteinuria in the second half of pregnancy, 
can be subclassified in a mild-moderate and a severe condition. The American College 
of Obstetricians and Gynecologists (ACOG) defines PE  as severe if blood pressure is 
>160 mmHg systolic and/or >110 mmHg diastolic or if proteinuria is >5 g/24 h.35 
Other criteria for severe PE are signs of systemic involvement like oliguria, cerebral 
disturbances, pulmonary edema, liver dysfunction, thrombocytopenia or fetal growth 
restriction.35 Next to  classification of the severity, PE  can also be defined as early-
onset (EOP) or late-onset (LOP). The most common used definition of early-onset PE 
in recent literature is the occurrence before 34 weeks of gestation.36 Maternal and fetal 
outcome post PE improve with a later manifestation of PE during pregnancy.21  
Future CVD risk is also different for women post early- and late-onset PE.37 It has been 
hypothesized that both conditions may have a different etiology, in which  EOP reflects 
a primary placental problem and LOP a predominant maternal constitutional 
syndrome.21,23 This is supported by abnormal placenta in EOP and a normal villous 
morphology of the placenta in LOP.38 Mukharjee et al. investigated the metabolic 
profiles of women with EOP and LOP with a Fourier transform infrared (FTIR) 
spectroscopy.39 They found a significantly higher atherosclerotic index for women with 
PE early in pregnancy. 
These findings are important for the interpretation of our data of the PREVFEM 
cohort, as described in CHAPTERS 4 to 6. The PREVFEM cohort consists of women 
with a history of very early PE, with a first onset before 32 weeks of gestation, 
therefore our findings cannot be generalized to all women with PE. In a sub-analysis of 
the PREVFEM study, serum levels of Anti-Müllerian hormone (AMH) were found to 
be significantly lower in women post PE compared to normotensive women.40 
Therefore, signs of a reduced ovarian reserve, as measured  by reduced AMH levels, 
may not only express signs of early biological aging, but also impairment of  vascular 
function.40  
 
PREVENTION 
Despite the abundant evidence of the increased CVD risk in women post PE, 
recommendations for the prevention of CVD in these high-risk subset of women are 
yet unclear. Several national and international guidelines advise to incorporate the 
obstetric history in the female cardiovascular risk assessment.41-43 The recently 
published stroke guidelines for women, from the American Heart Association and the 
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American Stroke Association, provide a number of follow up measures.44 Stroke is one 
of the major cardiovascular event entities,45 and risk of stroke post PE is increased with 
odds ratios up to 3.59.9,44 These new guidelines recommend to evaluate  all women 
starting at 6 months to 1 year postpartum after  a history of a HPD for the presence of 
CVD  risk factors like hypertension, obesity and dyslipidemia and to start treatment if 
needed (level of evidence class IIa).44 The authors do not make further 
recommendations on the frequency of postpartum follow-up and the executive clinician 
(general practitioner, obstetrician or cardiologist). 
Postpartum counseling and follow-up after a divers spectrum of pregnancy 
complications (almost 30% PE ) seems to be effective in the first year postpartum to 
identify women at risk for future CVD and is the first step to create awareness and 
initiate long-term prevention.46 Spaan et al. advise an individualized CVD risk 
management program which starts already at 6 weeks postpartum with CVD risk 
counseling and tailored lifestyle advise, followed by yearly CVD risk management by 
the general practitioner. 47  
However, literature on the (cost)effectiveness of long-term CVD screening and 
lifestyle interventions in women post PE is scarce. Berks et al. demonstrated an 
reduction of CVD risk in women post PE with adequate lifestyle interventions, with the 
important limitation that effect data of interventions in the general female population 
were used in their analysis.48 Postpartum weight interventions are effective in 
achieving weight loss, but again data in a specific population of women after HPD  are 
lacking.49 In our Markov model analysis (CHAPTER 7) we demonstrated the cost-
effectiveness of a yearly blood pressure measurement, including treatment of 
established hypertension, in women post early onset preeclampsia. In a time-horizon of 
20 years regularly blood pressure screening and early treatment gives an increment of 
12 days in perfect health, but a saving of €1,203 per person in 20 years. Future research 
should focus on the most appropriate timing and frequency of CVD prevention 
programs in women post HPD. Our Markov analysis is one of the first cost-
effectiveness studies on CVD prevention post PE, but shows that it might be effective 
to measure and treat blood pressure in young premenopausal women. This in 
disagreement with the Dutch CVD prevention guideline42, that advices risk evaluation 
in women post HPD after menopause. 
 
FUTURE PERSPECTIVES  
The increased lifetime CVD risk for women post HPD, especially post early-onset PE, 
needs more follow-up at intermediate and long term. The PREVFEM cohort has 
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focused at 10 years postpartum, when hypertension and abdominal obesity are the 
predominant risk factors. More data are needed on the development of lipid disorders, 
endothelial dysfunction and other pathophysiological parameters that may predict 
premature CVD events. 
Despite many unanswered questions, we can make some recommendations. Firstly, 
affected women need to be informed more thoroughly about the increased risk of future 
disease post HPD and the importance of a healthy lifestyle needs to be underscored. 
Secondary, awareness under healthcare workers, especially general practitioners and 
cardiologists, of HPD as a gender-specific risk factor needs to be established. The next 
step will be that all health care workers involved in CVD prevention should incorporate 
the obstetric history in their assessment procedure. As evidence on cost-effectiveness 
of counsel programs for women post PE is limited, we can now only recommend a  
yearly blood pressure check-up. As health care costs are rising steeply and young 
women want to participate actively in health prevention, other modalities of care are 
needed. The development of E-health programs with self-monitoring will facilitate 
patients and professionals (GPs and clinicians).50  
 
 
CONCLUSION 
 
Women with a history of HPD have increased CVD risk at intermediate term, which is 
mainly caused by increased blood pressure and obesity. Early life-style intervention 
and risk factor identification is needed to prevent premature manifestations of CVD 
events in this high risk subset of female patients. 
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Summary 
 
 
 
Cardiovascular disease (CVD) is one of the most important causes of death in Western 
world. The traditional risk factors, such as hypertension, dyslipidemia and diabetes, are 
well known. Recently the role of gender-specific risk factors has gained more attention. 
Hypertensive and metabolic pregnancy disorders are increasingly acknowledged as 
female specific risk factors for future cardiovascular disease. However until now data 
on CVD risk factor development at intermediate term are relatively scarce. Therefore, 
it is uncertain when preventive measures are needed and how they should be executed. 
In this thesis we examined the occurrence of traditional CVD risk factors in women 
with a history of a hypertensive pregnancy disorder (HPD), with a special focus on 
women post preeclampsia (PE). Furthermore we sought for potential markers of early 
cardiovascular disease and evaluated the cost-effectiveness of early hypertension 
screening in women after preeclampsia. We also investigated the association between a 
history of HPD and the presence, frequency, severity and intensity of vasomotor 
symptoms during menopause transition. 
 
CHAPTER 2 reviews the risk of future hypertension in women with a history of 
gestational hypertension (GH) and preeclampsia. GH is defined as hypertension (blood 
pressure above 140/90 mmHg) in the second half of pregnancy, PE is defined as 
hypertension in combination with proteinuria (>0.3 g/24 h) after 20 weeks of gestation. 
GH is generally considered the most benign condition of both; however, the reported 
relative risks (RR) of hypertension vary from 1.7 until 7.2 up to 16 years of follow-up. 
Risk of developing hypertension post PE is strongly related to the severity and timing 
of the PE during gestation. The RR is almost twice as high in women with a history of 
severe PE versus women with a history of mild PE (RR 6.0 vs 3.6, reference 1.0 
women with a normotensive pregnancy). As hypertension is a major CVD risk factor, 
early detection and treatment of hypertension might be an important element of 
prevention. 
 
In CHAPTER 3 we describe CVD risk factors in women with a history of hypertensive 
pregnancy disorders. For this study we included women, mean age 40 years, of the 
Doetinchem Cohort Study (1987-1991), a population-based study in de city of 
Doetinchem. History of HPD was assessed by questionnaires and included all 
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manifestations. Women with a history of HPD (n=689) had significantly higher 
systolic blood pressure (2.8 mmHg, 95%CI 1.7; 3.9), diastolic blood pressure (2.3 
mmHg, 95%CI 1.6; 3.0) and BMI (0.7 kg/m2, 95%CI 0.4; 1.1) than women with a 
normotensive pregnancy. We also evaluated the annual change for these parameters 
with ageing, which was comparable in both groups. Based on these data we do not 
advise long-term monitoring of CVD risk factors from pregnancy onwards in women 
after HPD. Future research should focus on the evaluation of individuals at higher risk 
and the lifetime development of CVD risk factors.   
 
CHAPTER 4 describes the presence of traditional CVD risk factors in the PReclampsia 
Risk Evaluation in FEMales (PREVFEM) cohort, a specific population of 339 women 
with a history of early preeclampsia (EOP) and 332 women with a normotensive 
pregnancy in history. This study was performed 10 years post index pregnancy to gain 
more insight into the intermediate CVD risk in women post PE. In this cohort we found 
an increased risk of hypertension (adjusted OR 3.6, 2.5; 5.2) and a higher risk of the 
metabolic syndrome (adjusted OR 2.2, 1.3; 3.5) for women post EOP in comparison 
with women after previous normotensive pregnancies. Body mass index (BMI) and 
waist circumference were significantly higher in women with a history of EOP 
compared to the reference women, however the prevalence of other traditional CVD 
risk factors like hypercholesterolemia and diabetes mellitus (DM) was not different 
between both groups.  
 
In CHAPTER 5, we describe ECG changes related to increased blood pressure and the 
effect of EOP on these changes. Non-specific ECG changes are useful in evaluating 
future CVD morbidity and mortality in hypertensive populations. We evaluated major 
and minor repolarization abnormalities, signs of left ventricular hypertrophy (LVH) 
and abnormalities in frontal T and QRS-T angles. In our cohort, both systolic blood 
pressure (SBP) and diastolic blood pressure (DBP) as well as stage 2 hypertension 
(defined as SBP >160 mmHg or DBP >100 mmHg) were significantly associated with 
LVH. There were no associations with the other evaluated ECG parameters. Although 
hypertension is significantly more prevalent in women with a history of EOP compared 
to reference women, 43% versus 17%, history of EOP was not associated with higher 
prevalences of ECG abnormalities. Based on these data we cannot recommend routine 
ECG screening for women with a history of EOP at ten years after index pregnancy.  
 
In CHAPTER 6, we evaluated CVD biomarker profiles in the PREVFEM cohort. 
Different predictive CVD biomarkers have been identified in recent years, in this 
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chapter we searched for various biomarkers in women with a history of preeclampsia. 
A subset of eight different biomarkers was investigated, reflecting inflammatory, 
metabolic, thrombotic and endothelial function markers.  
Associations between PE and these novel biomarkers were adjusted for traditional 
CVD risk factors. Women post PE had significantly higher levels of SE-selectin 
(adjusted difference 4.55, 99%CI 0.37; 8.74) and PAPPA (adjusted difference 19.08; 
99%CI 13.18; 24.99), whereas ApoB (adjusted difference -0.23, 99%CI -0.32; -0.14) 
was inversely associated with PE, Adiponectin, leptin, sICAM-1, sVCAM-1 and PAI-1 
were not different between affected women and the reference group. These results 
show that despite adjustment for traditional CVD risk factors, biomarker profiles for 
vascular dysfunction are different in women post PE compared to women with a 
normotensive pregnancy. More research is needed to clarify the prognostic impact and 
utility of these cardiovascular biomarkers in women post PE. 
 
In CHAPTER 7 we assessed the cost-effectiveness of screening and early treatment for 
hypertension in women after PE with a decision-analytic Markov model. Screening 
consisted of a postpartum annual blood pressure measurement during a timeframe of 
20 years by the general practitioner, whereas the non-intervention group did not receive 
any planned cardiovascular risk check-ups. Our hypothesis was that timely 
identification and adequate treatment of hypertension in women with a history of PE 
could decrease the risk on future CVD events and mortality with a reduction in 
associated health costs. Outcomes were measured in absolute costs, events, life-years 
and quality-adjusted life-years (QALYs). Over a 20 year time horizon events occurred 
in 0.072% of the population after screening, and in 0.085% of the population without 
screening. QALYs increased with an increment of 0.03 QALY (95%CI 0.01; 0.05), 
which means 12 days in perfect health. Total expected costs were €7,834 in the 
screening strategy, and €9,038 in the no screening strategy, an expected saving of 
€1,203 (95%CI -3223; -247) per person. The presented Markov model demonstrates 
that annual hypertension screening and treatment in primary care in women after PE 
might be cost-effective in preventing future CVD. However, the modest clinical effects 
and described assumptions should be taken into account before any recommendations 
according to screening programs post PE can be made.  
 
Endothelial dysfunction is known to play a role in the aetiology of HPD. Interestingly, 
endothelial dysfunction is also suggested to play a role in another female-specific 
cardiovascular risk factor, i.e. vasomotor menopausal symptoms (VMS), specifically 
night sweats and hot flushes. In CHAPTER 8 we evaluated whether there is an 
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association between HPD and VMS. For this purpose, we used data of the Kampen 
cohort, a database which consecutively included 853 women (mean age 55.5 years) 
who visited the outpatient cardiovascular clinic for women in Kampen between 2003 
and 2010. We found that, adjusted for potential confounders, VMS were more often 
present (OR 1.62, 95%CI 1.00; 2.63) and persisted more frequently longer that 1 year 
(OR 2.05, 95% CI 1.08; 3.89) among women with a history of HPD than among 
women with normotensive pregnancies. Other qualitative parameters, like severity, 
frequency and intensity of VMS, were not significantly different between both groups. 
This study was the first to show an association between previous HPD and VMS, a 
finding that needs confirmation in other populations. 
 
In CHAPTER 9 we discuss the clinical significance of our studies and the future 
perspectives of CVD prevention in women with a history of the different entities of 
HPD. At intermediate term the increased CVD is mainly caused by elevated blood 
pressure and obesity. For the long term, more prospective data are needed to 
investigate the development of lipid disorders, endothelial dysfunction and other 
pathophysiological parameters that may predict premature CVD events. Based on the 
data described in this thesis we recommend that both women with a history of HPD 
(and mainly post PE) and health care workers need to be more aware on the predictive 
role of HPD on future CVD risk and the importance of a healthy lifestyle with early 
CVD risk factor identification in these high risk subset of women. 
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Samenvatting  
 
 
 
Hart- en vaatziekten (HVZ) behoren tot de meest belangrijke oorzaken van sterfte in de 
Westerse wereld. De impact van de traditionele risicofactoren, zoals hypertensie, 
diabetes mellitus, hyperlipidemie en roken, is bekend. De laatste jaren wordt ook de rol 
van vrouwspecifieke risicofactoren steeds duidelijker. Hoge bloeddruk in de 
zwangerschap en andere metabole zwangerschapsaandoeningen worden gezien als 
belangrijke risicofactoren voor toekomstig hart- en vaatziekten. Op dit moment is het 
nog niet bekend hoe en op welke termijn na de zwangerschap deze factoren kunnen 
leiden tot een verhoogd risico. Om die reden is het dan ook onduidelijk of er 
preventieve maatregelen genomen moeten worden. 
In deze thesis onderzoeken wij de ontwikkeling van de traditionele risicofactoren voor 
HVZ bij vrouwen die een hypertensieve zwangerschapscomplicatie hebben 
doorgemaakt. Hierbij focussen wij vooral op vrouwen met een doorgemaakte 
preeclampsie (PE). Naast een onderzoek naar de ontwikkeling van cardiale 
risicofactoren bij vrouwen met PE in vergelijking met vrouwen zonder hypertensie in 
de zwangerschap, beoordelen wij of het kosteneffectief is om vrouwen na een 
doorgemaakte PE jaarlijks in de eerste lijn te screenen op hypertensie. Verder hebben 
wij de onderlinge relatie onderzocht tussen hypertensieve zwangerschapsaandoeningen 
en vasomotore symptomen in de menopauze (opvliegers en nachtzweten). 
 
In HOOFDSTUK 2 evalueren wij de bestaande literatuur ten aanzien van het toekomstige 
risico op hypertensie bij vrouwen met een doorgemaakte zwangerschapshypertensie en 
PE. Hypertensie in de zwangerschap (GH) is gedefinieerd als een bloeddruk boven de 
140/90 mmHg in het tweede semester van de zwangerschap, in geval van PE gaat deze 
hypertensie ook gepaard met proteïnurie (0,3 g/24 h). Zwangerschapshypertensie wordt 
over het algemeen gezien als een relatief milde complicatie, waarbij er in de literatuur 
toch een relatief risico (RR) op toekomstige hypertensie gevonden wordt van 1,7 tot 
7,2 maal het risico ten opzichte van normotensieve zwangerschappen bij een follow-up 
tot 16 jaar. Voor vrouwen met een doorgemaakte PE is dit toekomstige risico op 
hypertensie afhankelijk van de ernst en het tijdstip van ontstaan van de PE in de 
zwangerschap. Ernstige PE geeft een bijna tweemaal zo hoog risico op hypertensie als 
een milde PE, RR 6,0 vs 3,6, ten opzichte van vrouwen die een normotensieve 
zwangerschap hebben doorgemaakt (RR 1,0). 
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In HOOFDSTUK 3 evalueren wij de aanwezigheid van risicofactoren voor HVZ bij 
vrouwen met een voorgeschiedenis van hypertensieve zwangerschapsaandoeningen 
(zowel GH als PE). Deze studie voerden wij uit onder alle vrouwen uit de Doetinchem 
Cohort Study (1987-1991), een populatie studie in de stad Doetinchem. De gemiddelde 
leeftijd van deze vrouwen was 40 jaar. Een voorgeschiedenis van hypertensieve 
zwangerschapscomplicaties werd vastgesteld aan de hand van een vragenlijst. In dit 
cohort vonden wij dat vrouwen met hypertensieve zwangerschapscomplicaties (n=689) 
vergeleken met vrouwen met een normotensieve zwangerschap in het verleden 
(n=2.703) een significant hogere systolische bloeddruk (2,8 mmHg, 95%BI 1,7; 3,9); 
diastolische bloeddruk (2,3 mmHg, 95%BI 1,6;3,0) en BMI (0,7 kg/m2, 95%BI 0,4; 
1,1) hadden. De lipiden waarden (totaal en HDL cholesterol) waren gelijk in beide 
groepen. De jaarlijkse veranderingen in alle parameters met het toenemen van de 
leeftijd waren gelijk in beide groepen. Op basis van deze data is geen lange termijn 
advies te geven voor het monitoren van cardiale risicofactoren na een hypertensieve 
zwangerschap.  
 
In HOOFDSTUK 4 beschrijven wij het voorkomen van de traditionele risicofactoren voor 
HVZ in het PREVFEM (PReclampsia Risk EValuation in FEMales) cohort, een 
populatie bestaande uit 339 vrouwen die een vroege PE hebben doorgemaakt en een 
groep van 332 vrouwen die een normotensieve zwangerschap hebben doorgemaakt. 
Deelnemers aan dit onderzoek werden gemiddeld 10 jaar na de index zwangerschap 
opgeroepen voor een poliklinisch cardiaal screeningsonderzoek bestaande uit een 
vragenlijst, lichamelijk onderzoek, ECG registratie en laboratoriumonderzoek. Bij 
vrouwen na een doorgemaakte PE vonden wij een verhoogd risico op hypertensie (OR 
3,6, BI 2,5; 5,2) en het metabole syndroom (OR 2,2, BI 1,3; 3,5) in vergelijking met 
vrouwen die een ongecompliceerde zwangerschap hadden  doorgemaakt. Wij vonden 
geen verschil in het voorkomen van diabetes mellitus en hypercholesterolemie tussen 
beide groepen.  
 
Vervolgens hebben wij in HOOFDSTUK 5 onderzocht of de gemaakte ECG registraties 
verschilden tussen vrouwen met en zonder doorgemaakte PE in het PREVFEM cohort. 
Wij onderzochten de aanwezigheid van (aspecifieke) repolarisatie stoornissen, 
aanwijzingen voor linkerventrikelhypertrofie (LVH) en afwijkingen in de frontale T en 
QRS-T assen. In het PREVFEM cohort waren zowel de systolische bloeddruk (SBP), 
diastolische bloeddruk (DBP) en stadium 2 hypertensie (gedefinieerd als SBP >160 
mmHg of DBP >100 mmHg) significant geassocieerd met de aanwezigheid van LVH. 
Er waren geen associaties met andere ECG parameters. Hoewel hypertensie significant 
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meer voorkwam  bij  vrouwen met een voorgeschiedenis van PE vergeleken met de 
referentie groep, 43% versus 17% (zie HOOFDSTUK 3), was vroege PE niet 
geassocieerd met meer ECG afwijkingen. Op basis van deze gegevens adviseren wij 
om niet routinematig een ECG te maken bij vrouwen in deze levensfase na een 
doorgemaakte PE.  
 
In HOOFDSTUK 6 hebben wij een aantal cardiovasculaire biomarkers onderzocht in het 
PREVFEM cohort. In de laatste jaren zijn er verschillende biomarkers geïdentificeerd 
die het risico op HVZ kunnen voorspellen. Wij hebben acht verschillende biomarkers 
onderzocht, die betrekking hebben op zowel de inflammatoire, metabole, trombotische 
als de endotheelfunctie. Associaties tussen PE en deze biomarkers werden gecorrigeerd 
voor de aanwezigheid van traditionele cardiovasculaire risico factoren. Vrouwen na 
een doorgemaakte PE hadden een significant hoger niveau van SE-selectin 
(gecorrigeerd verschil 4,55, 99%BI 0,37; 8,74) en PAPPA (gecorrigeerd verschil 
19,08; 99%BI 13,18; 24,99), terwijl ApoB (gecorrigeerd verschil -0,23 99%BI -0,32; -
0,14) significant lager was bij vrouwen na PE, vergeleken met de referentiegroep. 
Adiponectin, leptin, sICAM-1, sVCAM-1 en PAI-1 waren niet verschillend tussen 
beide groepen. Deze resultaten laten zien dat de vasculaire functie anders is bij 
vrouwen na een doorgemaakte PE ten opzichte van vrouwen na een normotensieve 
zwangerschap, en niet volledig verklaard kan worden door de verschillende in 
traditionele risicofactoren voor HVZ. Meer onderzoek is nodig om de rol en de 
prognostische impact van de diverse cardiovasculaire biomarkers bij vrouwen na een 
doorgemaakte PE te bepalen. 
 
In HOOFDSTUK 7 analyseren wij de kosteneffectiviteit van screening en vroege 
behandeling van hypertensie bij vrouwen met een voorgeschiedenis van PE door 
middel van een Markov model. Wij onderzochten of een jaarlijkse bloeddrukcontrole 
bij de huisarts vanaf het eerste jaar postpartum gedurende een tijdsbestek van 20 jaar 
kosteneffectief is. Onze hypothese daarbij was dat vroeg identificatie en behandeling 
van hypertensie bij vrouwen na een doorgemaakte PE het risico op toekomstig HVZ 
kan reduceren met een vermindering in zorgkosten. Uitkomsten werden gemeten in 
absolute kosten, het voorkomen van events, het aantal levensjaren en de voor kwaliteit-
van-leven gecorrigeerde levensjaren (quality-adjusted life-years, QALYs). Gedurende  
een periode van 20 jaren zullen er 0,072% events voorkomen in de gescreende groep 
en 0,085% in de niet gescreende groep. De QALYs nemen toe met 0,03 (95% BI 0,01; 
0,05), dit betekent 12 extra dagen in goede gezondheid. De totale verwachte kosten per 
vrouw (inclusief screening, behandeling hypertensie en cardiovasculaire zorgkosten) 
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zullen €7.834 zijn in de screening strategie, ten opzichte van €9.038 in de niet-
screening strategie. Dat is een besparing van €1.204 (95% BI -3223; -247) per persoon. 
Uit de resultaten van dit Markov model concluderen wij dat een jaarlijkse screening en 
vroege behandeling van hypertensie bij vrouwen na een PE kosten kan besparen. De 
klinische effectiviteit is echter beperkt en afhankelijk van een aantal aannames zoals 
beschreven in hoofdstuk 7. 
 
Endotheel dysfunctie speelt een belangrijke rol in de etiologie van hypertensieve 
zwangerschapscomplicaties, met name PE. Dit  mechanisme speelt mogelijk ook een 
rol bij andere vrouwspecifieke risicofactoren voor HVZ. In HOOFDSTUK 8 onderzoeken 
wij de relatie tussen hypertensieve zwangerschapscomplicaties en het voorkomen van 
vasomotore symptomen in de menopauze (VMS), zoals opvliegers en nachtzweten. 
Hiervoor hebben wij  gebruikt gemaakt van data uit het Kampen cohort.  Hierin zijn de 
gegevens verzameld van 853 vrouwen (gemiddelde leeftijd 55,5 jaar) die tussen 2003 
en 2010 de cardiologische polikliniek voor vrouwen in Kampen bezocht hebben. Wij 
vonden dat VMS vaker aanwezig waren bij vrouwen met een doorgemaakte 
hypertensieve zwangerschap in het verleden ten opzichte van vrouwen zonder een 
dergelijke zwangerschap (OR 1,62, 95% BI 1,00;2,63). Ook hadden vrouwen na een 
zwangerschapshypertensie vaker langer dan 1 jaar VMS (OR 2,05, 95% BI 1,08;3,89) 
dan de vrouwen in de referentiegroep. Andere kwalitatieve parameters zoals de ernst, 
frequentie en intensiteit van de VMS waren niet verschillende tussen beide groepen. 
Aangezien deze studie de eerste is die een associatie tussen hypertensieve 
zwangerschapscomplicaties en VMS heeft aangetoond,  is meer onderzoek in andere 
populaties nodig om deze associatie te bevestigen. 
 
 
In HOOFDSTUK 9 bediscussiëren wij de klinische betekenis van de beschreven studies 
en de aanbevelingen voor preventie bij vrouwen na hypertensieve zwangerschaps-
complicaties. Op de middellange termijn na de indexzwangerschap wordt het 
verhoogde risico op HVZ vooral veroorzaakt door een verhoogde bloeddruk en 
(abdominale) obesitas. Voor de langere termijn is meer informatie nodig over de 
ontwikkeling van lipidenafwijkingen, insulineresistentie en andere metabole 
parameters die de pathofysiologie van premature HVZ kunnen voorspellen in deze 
vrouwen. Gebaseerd op onze onderzoeksgegeven adviseren wij om vrouwen na een 
hypertensieve zwangerschap, en vooral na een doorgemaakte PE, in eerste instantie te 
monitoren voor een gezonde leefstijl en alert te zijn op de voege ontwikkeling van 
hypertensie. 
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Dankwoord 
 
 
 
Het is zover, na een aantal jaar hard werken is dit proefschrift tot stand gekomen. Vele 
mensen hebben hier de afgelopen jaren aan meegewerkt en een aantal wil ik hierbij in 
het bijzonder bedanken. 
Allereerst mijn promotor prof. dr. A.H.E.M. Maas, lieve Angela, aan jouw ben ik veel 
dank verschuldigd. Zonder je overtuigingskracht was er geen proefschrift geweest, 
want ‘onderzoek doen’ was tenslotte niets voor mij. Ik kwam als co-assistent bij je op 
gesprek om een wetenschappelijke stage te bespreken, die kwam er ook, maar jij had 
ondertussen al verdere plannen, er zou ook een proefschrift komen. Jij hebt me als co-
assistent onder je vleugels genomen en geïnspireerd de afgelopen jaren. Ik heb veel 
geleerd door onze samenwerking en kon altijd bij je terecht ondanks je drukke agenda. 
Daarnaast heb ik ook goede herinneringen aan onze gezamenlijke uitstapjes, ondermeer 
Berlijn en TelAviv, naast het wetenschappelijke was daar ook altijd tijd voor 
gezelligheid en cultuur. Ik heb een enorme bewondering voor je visie en motivatie 
binnen je werkgebied en ik ben er trots op je eerste promovendus te mogen zijn.  
Daarnaast mijn promotor prof. dr. Y.T. van der Schouw, beste Yvonne, jij hebt dit 
Zwolse project onder je hoede genomen en ons bijgestuurd waar nodig. Jij bent als 
geen ander in staat om het overzicht te bewaren of te herstellen en daarmee de nodige 
vervolgstappen inzichtelijk te maken. Jouw vermogen om in een zin tot de kern van de 
boodschap te komen is indrukwekkend en enorm behulpzaam geweest gedurende het 
traject.  
Ganiye Arpaci, jij bent met veel enthousiasme aan dit gezamenlijke project begonnen. 
Gaandeweg heb ik het stokje van je overgenomen, maar ik ben je erg erkentelijk voor 
al het werk dat jij in het PREVFEM cohort hebt gestoken.  
De overige co-auteurs, dr. J.P.O. Ottervanger en prof. dr. M.J. de Boer, wil ik ook 
bedanken voor hun bijdrage aan dit proefschrift en de geïnvesteerde tijd en energie. 
Dr. J. van Eyck, hartelijk dank voor het ter beschikking stellen van de Zwolse 
preeclampsie database, deze dames vormen de basis van dit proefschrift. Dank voor het 
nuttige commentaar bij het doornemen van de manuscripten. 
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Dr. G.C. Herber-Gast, beste Gerrie-Cor, letterlijk op grote afstand heb jij een 
structurele bijdrage geleverd aan het ‘Kampen-artikel’. Van overgangsklachten wist ik 
nog erg weinig, maar gelukkig heb jij me alle ins-en-outs kunnen bijbrengen. Veel 
succes met je werkzaamheden in Australië. 
Prof. dr. M.W.W. Verschuren, beste Monique, dank voor de samenwerking met het 
RIVM bij de analyse van zwangerschapshypertensie in het Doetinchem Cohort en de 
tijd die je geïnvesteerd hebt in het artikel. Ik heb veel geleerd van het werken met jullie 
medewerkers en heb het een voorrecht gevonden met de indrukwekkend Doetinchem 
database te mogen werken.  
Prof. dr. J. de Graaf, dank voor het nuttige commentaar op het biomarker stuk. 
Daarnaast ben ik ook er blij dat u hebt willen plaats nemen in de leescommissie.  
Ook de overige medeauteurs van het biomarker stuk, dr. L. Joosten en dr. S. Holewijn, 
dank voor jullie bijdrage. 
Dr. J.P.C. Grutters, beste Janneke, dank voor je hulp bij het opzetten van een 
kosteneffectiviteitsanalyse naar preventiemogelijkheden bij vrouwen postpreeclampsie. 
Het was voor ons een grote wens om het proefschrift af te sluiten met een 
kosteneffectiviteitsanalyse, jij bent met ons die uitdaging aan gegaan en hebt ons door 
de analyses heen geloodst.  
Prof. G.J. van der Wilt, dank voor de ondersteuning bij de kosteneffectiviteitsanalyse 
en het zinvolle commentaar op het manuscript.  
De mensen van Diagram, dank zij jullie is het PREVFEM cohort tot stand gekomen en 
jullie hebben al die jaren zorg gedragen voor het verzamelen en beheren van de data.  
Karin Nijenbrinks, dank zij jou begon dit project met een keurig verzorgd 
onderzoeksprotocol, gedurende de jaren heb jij ook altijd een vinger aan de pols 
gehouden.  
Helena Muilwijk, vanaf het begin ben jij betrokken geweest bij dit project en heb je vol 
enthousiasme ongelooflijk veel werk voor ons verzet. Jij had altijd het overzicht over 
onze contacten en wist precies wat er nog moest gebeuren. Dank voor alle 
ondersteuning en de vele uren die je geïnvesteerd hebt. 
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Alle dames die de PREVFEM poli hebben gedraaid: Mirjam Vrolijk, Angela Nieuwveld, 
Anneke Fransen en Hettie Versteeg, dank voor jullie inzet en enthousiasme. 
Anouk Wienke, Evelien Kolkman en Sonja Postma, dank voor het aanleveren van de 
datasets. En daarnaast hebben jullie waar nodig ook gefungeerd als statistische 
helpdesk, dank voor jullie hulp. 
Edwin Nibbering en Lies Georg, het heeft veel energie en tijd gekost, maar jullie waren 
uiteindelijk in staat om alle ECG gegevens digitaal ter analyse aan te bieden. Zonder 
jullie hulp hadden we nog heel veel uurtjes statusonderzoek moeten doen.  
Anita Kloosterman, lieve Anita, vanaf het begin af aan ben jij bij dit project betrokken 
geweest en heb je ervoor gezorgd dat alles op rolletjes bleef lopen. Daarnaast heb ik 
ook hele goede herinneringen aan onze gezamenlijke tripjes. Inmiddels ben jij 
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